Substituted nicotinamides as kcnq2/3 modulators

ABSTRACT

The invention relates to substituted nicotinamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

The invention relates to substituted nicotinamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

The treatment of pain, in particular of neuropathic pain, is of great importance in medicine. There is a worldwide need for effective pain therapies. The urgent need for action for a target-orientated treatment of chronic and non-chronic states of pain appropriate for the patient, by which is to be understood the successful and satisfactory treatment of pain for the patient, is also documented in the large number of scientific works which have recently been published in the field of applied analgesics and of fundamental research into nociception.

A pathophysiological feature of chronic pain is the overexcitability of neurons. Neuronal excitability is influenced decisively by the activity of K⁺ channels, since these determine decisively the resting membrane potential of the cell and therefore the excitability threshold. Heteromeric K⁺ channels of the molecular subtype KCNQ2/3 (Kv7.2/7.3) are expressed in neurons of various regions of the central (hippocampus, amygdala) and peripheral (dorsal root ganglia) nervous system and regulate the excitability thereof. Activation of KCNQ2/3 K⁺ channels leads to a hyperpolarization of the cell membrane and, accompanying this, to a decrease in the electrical excitability of these neurons. KCNQ2/3-expressing neurons of the dorsal root ganglia are involved in the transmission of nociceptive stimuli from the periphery into the spinal marrow (Passmore et al., J. Neurosci. 2003; 23(18): 7227-36).

It has accordingly been possible to detect an analgesic activity in preclinical neuropathy and inflammatory pain models for the KCNQ2/3 agonist retigabine (Blackburn-Munro and Jensen, Eur J. Pharmacol. 2003; 460(2-3); 109-16; post et al., Naunyn Schmiedebergs Arch Pharmacol 2004; 369(4): 382-390).

The KCNQ2/3 K⁺ channel thus represents a suitable starting point for the treatment of pain; in particular of pain selected from the group consisting of chronic pain, neuropathic pain, inflammatory pain and muscular pain (Nielsen et al., Eur J. Pharmacol. 2004; 487(1-3): 93-103), in particular of neuropathic and inflammatory pain.

Moreover, the KCNQ2/3 K⁺ channel is a suitable target for therapy of a large number of further diseases, such as, for example, migraine (US2002/0128277), cognitive diseases (Gribkoff, Expert Opin Ther Targets 2003; 7(6): 737-748), anxiety (Korsgaard et al., J Pharmacol Exp Ther. 2005, 14(1): 282-92), epilepsy (Wickenden et al., Expert Opin Ther Pat 2004; 14(4): 457-469; Gribkoff, Expert Opin Ther Targets 2008, 12(5): 565-81; Miceli et al., Curr Opin Pharmacol 2008, 8(1): 65-74), urinary incontinence (Streng et al., J Urol 2004; 172: 2054-2058), dependency (Hansen et al., Eur J Pharmacol 2007, 570(1-3): 77-88), mania/bipolar disorders (Dencker et al., Epilepsy Behav 2008, 12(1): 49-53), dystonia-associated dyskinesias (Richter et al., Br J Pharmacol 2006, 149(6): 747-53).

There is a need for further compounds with comparable or better properties, not only in respect of affinity for KCNQ2/3 as such (potency, efficacy).

For example, it can be advantageous to improve the metabolic stability, the solubility in aqueous media or the permeability of the compounds. These factors can have a positive effect on the oral bioavailability or can change the PK/PD (pharmacokinetic/pharmacodynamic) profile, which can lead, for example, to a more advantageous duration of action.

A weak or non-existent interaction with transporter molecules, which are involved in the uptake and excretion of medicaments, is also to be categorized as an indication of improved bioavailability and low medicament interactions. Further, interactions with the enzymes that are involved in the degradation and excretion of medicaments should also be as low as possible, because such test results likewise indicate that low or no medicament interactions at all are to be expected.

It can also be advantageous for the compounds to exhibit a high selectivity in respect of other receptors of the KCNQ family (specificity), for example in respect of KCNQ1, KCNQ3/5 or KCNQ4. A high selectivity can have a positive effect on the side-effect profile. For example, it is known that compounds which (also) bind to KCNQ1 involve a high risk of cardiac side-effects, for which reason high selectivity in respect of KCNQ1 can be desirable. However, a high selectivity in respect of other receptors can also be advantageous. A low affinity for the hERG ion channel or for the L-type calcium ion channel (phenylalkylamine, benzothiazepine, dihydropyridine binding sites) can be advantageous because those receptors are associated with the occurrence of cardiac side-effects. Overall, an improved selectivity in respect of the binding to other endogenous proteins (i.e. e.g. receptors or enzymes) can lead to an improvement in the side-effect profile and hence to improved tolerability.

An object of the invention was, therefore, to provide novel compounds which have advantages over the compounds of the prior art. The compounds should be suitable in particular as pharmacological active ingredients in medicaments, especially in medicaments for the treatment of disorders or diseases that are mediated at least in part by KCNQ2/3 K⁺ channels.

That object is achieved by the subject-matter of the patent claims.

Substituted aryl- or heteroaryl-amides which are suitable as antagonists of the EP₄ receptor are known from the prior art (WO 2005/105733). Also known are compounds which are suitable as inhibitors of the DPP-IV enzyme (WO 2007/015767) and of the 11-β-HSD1 enzyme (WO 2008/012532).

It has been found, surprisingly, that substituted nicotinamides of the general formula (1) below are suitable for the treatment of pain. It has further been found, surprisingly, that substituted nicotinamides of the general formula (1) below also have an excellent affinity for the KCNQ2/3 K⁺ channel and are therefore suitable for the treatment of disorders or diseases that are mediated at least in part by KCNQ2/3 K⁺ channels. The substituted nicotinamides thereby act as modulators, that is to say agonists or antagonists, of the KCNQ2/3 K⁺ channel.

The invention provides substituted nicotinamides of the general formula (1)

wherein A¹ represents CR¹⁰R¹¹ or S; A² represents CR¹²R¹³, C(═O), O, S, S(═O) or S(═O)₂; R¹ represents C₁₋₁₀-alkyl or C₂₋₁₀-heteroalkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; or C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; CH₂—O-methyl; CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl, S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; NR^(a)R^(b), wherein R^(a) and R^(b) each independently of the other represents H or C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted, or R^(a) and R^(b), together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; C₁₋₁₀-alkyl, C₂₋₁₀-heteroalkyl, O—C₁₋₁₀-alkyl or S—C₁₋₁₀-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₁₀-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted;

-   -   with the proviso that when R⁵, R⁶, R⁷ and R⁸ each denotes H and         A¹ represents S, A² may not denote S, S(═O) or S(═O)₂;         or R⁵ and R⁶ or R⁷ and R⁸ or R¹⁰ and R¹¹ or R¹² and R¹³ or R⁵         and R¹¹ or R⁵ and R⁷ or R⁵ and R¹³ or R⁷ and R¹³ or R⁷ and R¹¹         or R¹¹ and R¹³, together with the carbon atom(s) joining them,         form a C₃₋₈-cycloalkyl or a heterocyclyl having from three to         eight ring members, in each case saturated or unsaturated,         unsubstituted or mono- or poly-substituted; wherein the         remaining substituents R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ in         each case have the meaning given above;         R⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in each case         saturated or unsaturated, unsubstituted or mono- or         poly-substituted; aryl or heteroaryl, in each case unsubstituted         or mono- or poly-substituted; or represents CR^(c)R^(d), wherein         R^(c) and R^(d) each independently of the other denotes         C₁₋₄-alkyl, in each case saturated or unsaturated, branched or         unbranched, unsubstituted or mono- or poly-substituted;     -   with the proviso that when A² represents O or S and R⁹         represents heterocyclyl, saturated or unsaturated, unsubstituted         or mono- or poly-substituted; or heteroaryl, unsubstituted or         mono- or poly-substituted, the bonding of the heteroaryl or         heterocyclyl takes place via a carbon atom of the heteroaryl or         heterocyclyl;         wherein “alkyl substituted”, “heteroalkyl substituted”,         “heterocyclyl substituted” and “cycloalkyl substituted” denote         the substitution of one or more hydrogen atoms, in each case         independently of one another, by F; Cl; Br; I; NO₂; CF₃; CN; ═O;         C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl;         C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or         C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or         heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl;         CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂;         C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl;         C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂;         C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl);         C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃;         O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl;         O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl;         O—C(═O)heteroaryl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂;         NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-O(═O)C₁₋₈-alkyl;         N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH;         S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl;         S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH;         S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl;         S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; and         S(═O)₂—NH—C₁₋₈-heteroaryl;         wherein “aryl substituted” and “heteroaryl substituted” denote         the substitution of one or more hydrogen atoms, in each case         independently of one another, by F; Cl; Br; I; NO₂; CF₃; CN;         C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl;         C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or         C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or         heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl;         CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂;         C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl;         C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂;         C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl);         C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃;         O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl;         O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl;         O—C(═O)heteroaryl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂;         NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-O(═O)C₁₋₈-alkyl;         N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—O(═O)-heteroaryl; SH;         S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl;         S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH;         S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl;         S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; S(═O)₂—NH—C₁₋₈-heteroaryl;         in the form of the free compounds or salts of physiologically         acceptable acids or bases.

Within the scope of this invention, the terms “alkyl” or “C₁₋₁₀-alkyl”, “C₁₋₈-alkyl”, “C₁₋₆-alkyl”, “C₁₋₄-alkyl”, “C₁₋₂-alkyl” and “C₂₋₆-alkyl” include acyclic saturated or unsaturated aliphatic hydrocarbon radicals, which can be branched or unbranched as well as unsubstituted or mono- or poly-substituted, having from 1 to 10 or from 1 to 8 or from 1 to 6 or from 1 to 4 or from 1 to 2 or from 2 to 6 carbon atoms, that is to say C₁₋₁₀-alkanyls, C₂₋₁₀-alkenyls and C₂₋₁₀-alkynyls or C₁₋₈-alkanyls, C₂₋₈-alkenyls and C₂₋₈-alkynyls or C₁₋₆-alkanyls, C₂₋₆-alkenyls and C₂₋₆-alkynyls or C₁₋₄-alkanyls, C₂₋₄-alkenyls and C₂₋₄-alkynyls or C₁₋₂-alkanyls, C₂-alkenyls and C₂-alkynyls or C₂₋₆-alkanyls, C₂₋₆-alkenyls and C₂₋₆-alkynyls. Alkenyls contain at least one C—C double bond and alkynyls contain at least one C—C triple bond. Alkyl is preferably selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, ethenyl (vinyl), ethynyl, propenyl (—CH₂CH═CH₂, —CH═CH—CH₃, —C(═CH₂)—CH₃), propynyl (—CH—C≡CH, —C≡C—CH₃), butenyl, butynyl, pentenyl, pentynyl, hexenyl and hexynyl, heptenyl, heptynyl, octenyl, octynyl, nonenyl, nonynyl, decenyl and decynyl.

Within the scope of this invention, the terms “heteroalkyl” or “C₂₋₁₀-heteroalkyl” and “C₂₋₈-heteroalkyl” include acyclic aliphatic saturated or unsaturated hydrocarbon radicals having from 2 to 10 carbon atoms, that is to say C₂₋₁₀-heteroalkanyls, C₂₋₁₀-heteroalkenyls and C₂₋₁₀-heteroalkynyls, or having from 2 to 8 carbon atoms, that is to say C₂₋₈-heteroalkanyls, C₂₋₈-heteroalkenyls and C₂₋₈-heteroalkynyls, which in each case can be branched or unbranched as well as unsubstituted or mono- or poly-substituted and in which at least one carbon atom, optionally also two or three carbon atoms, have been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, N, NH and N(C₁₋₈-alkyl), preferably N(CH₃), wherein the initial carbon atom of a C₂₋₁₀-heteroalkyl or of a C₂₋₈-heteroalkyl, via which the C₂₋₁₀-heteroalkyl or C₂₋₈-heteroalkyl is bonded to the respective general structure of higher order, cannot be replaced by a heteroatom or heteroatom group and adjacent carbon atoms cannot simultaneously be replaced by a heteroatom or heteroatom group. The heteroatom groups NH and N(C₁₋₈-alkyl) of the heteroalkyl can optionally be mono- or poly-substituted. C₂₋₁₀-Heteroalkenyls and C₂₋₈-heteroalkenyls contain at least one C—C or C—N double bond and C₂₋₁₀-heteroalkynyls and C₂₋₈-heteroalkynyls contain at least one C—C triple bond. Heteroalkyl is preferably selected from the group comprising —CH₂—O—CH₃, —CH₂—CH₂—O—CH₃, —CH₂—CH₂—O—CH₂—CH₃, —CH₂—CH₂—O—CH₂—CH₂—O—CH₃, —CH═CH—O—CH₃, —CH═CH—O—CH₂—CH₃, ═CH—O—CH₃, ═CH—O—CH₂—CH₃, ═CH—CH₂—O—CH₂—CH₃, ═CH—CH₂—O—CH₃, —CH₂—NH—CH₃, —CH₂—CH₂—NH—CH₃, —CH₂—CH₂—NH—CH₂—CH₃, —CH₂—CH₂—NH—CH₂—CH₂—NH—CH₃, —CH═CH—NH—CH₃, —CH═CH—NH—CH₂—CH₃, —CH═CH—N(CH₃)—CH₂—CH₃, ═CH—NH—CH₃, ═CH—NH—CH₂—CH₃, ═CH—CH₂—NH—CH₂—CH₃, ═CH—CH₂—NH—CH₃, —CH₂—N(CH₃)—CH₃, —CH₂—CH₂—N(CH₃)—CH₃, —CH₂—CH₂—N(CH₃)—CH₂—CH₃, —CH₂—CH₂—N(CH₃)—CH₂—CH₂—N(CH₃)—CH₃, CH₂—CH₂—NH—CH₂—CH₂—O—CH₃, CH₂—CH₂—O—CH₂—CH₂—NH—CH₃, CH₂—CH₂—N(CH₃)—CH₂—CH₂—O—CH₃, CH₂—CH₂—O—CH₂—CH₂—N(CH₃)—CH₃, CH₂—NH—CH₂—O—CH₃, CH₂—O—CH₂—NH—CH₃, CH₂—N(CH₃)—CH₂—O—CH₃, CH₂—O—CH₂—N(CH₃)—CH₃, —CH═CH—N(CH₃)—CH₃, ═CH—N(CH₃)—CH₃, ═CH—N(CH₃)—CH₂—CH₃, ═CH—CH₂—N(CH₃)—CH₂—CH₃, ═CH—CH₂—N(CH₃)—CH₃, —CH₂—CH₂═N(CH₃) and —CH₂═N(CH₃).

For the purposes of this invention, the terms “cycloalkyl” or “C₃₋₁₀-cycloalkyl”, “C₃₋₇-cycloalkyl” and “C₃₋₈-cycloalkyl” denote cyclic aliphatic hydrocarbons having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms or having 3, 4, 5, 6 or 7 carbon atoms or having 3, 4, 5, 6, 7 or 8 carbon atoms, wherein the hydrocarbons can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or poly-substituted. The bonding of the cycloalkyl to the general structure of higher order can take place via any desired and possible ring member of the cycloalkyl radical. The cycloalkyl radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, that is to say with cycloalkyl, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. The cycloalkyl radicals can further be bridged one or more times, as, for example, in the case of adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Cycloalkyl is preferably selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, adamantyl,

cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

The term “heterocyclyl” or “heterocycloalkyl” includes aliphatic saturated or unsaturated (but not aromatic) cycloalkyls having from three to ten, that is to say 3, 4, 5, 6, 7, 8, 9 or 10, ring members, in which at least one carbon atom, optionally also two or three carbon atoms, has been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, S, N, NH and N(C₁₋₈-alkyl), preferably N(CH₃), wherein the ring members can be unsubstituted or mono- or poly-substituted. The bonding of the heterocyclyl to the general structure of higher order can take place via any desired and possible ring member of the heterocyclyl radical. The heterocyclyl radicals can also be fused with further saturated, (partially) unsaturated (hetero)cyclic or aromatic or heteroaromatic ring systems, that is to say with cycloalkyl, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Heterocyclyl radicals are preferably selected from the group comprising azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, pyrrolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydro-pyrrolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydro-indolinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrahydro-pyridoindolyl, tetrahydronaphthyl, tetrahydrocarbolinyl, tetrahydroisoxazolopyridinyl, thiazolidinyl and thiomorpholinyl.

Within the scope of this invention, the term “aryl” denotes aromatic hydrocarbons having up to 14 ring members, inter alia phenyls and naphthyls. Each aryl radical can be unsubstituted or mono- or poly-substituted, it being possible for the aryl substituents to be identical or different and to be in any desired and possible position of the aryl. The aryl can be bonded to the general structure of higher order via any desired and possible ring member of the aryl radical. The aryl radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cyclic, aromatic or heteroaromatic ring systems, that is to say with cycloalkyl, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Examples of fused aryl radicals are benzodioxolanyl and benzodioxanyl. Aryl is preferably selected from the group containing phenyl, 1-naphthyl and 2-naphthyl, each of which can be unsubstituted or mono- or poly-substituted. A particularly preferred aryl is phenyl, unsubstituted or mono- or poly-substituted.

The term “heteroaryl” denotes a 5- or 6-membered cyclic aromatic radical which contains at least 1 heteroatom, optionally also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are in each case selected independently of one another from the group S, N and O and the heteroaryl radical can be unsubstituted or mono- or poly-substituted; in the case of substitution on the heteroaryl, the substituents can be identical or different and can be in any desired and possible position of the heteroaryl. Bonding to the general structure of higher order can take place via any desired and possible ring member of the heteroaryl radical. The heteroaryl can also be part of a bi- or poly-cyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated, (hetero)cyclic or aromatic or heteroaromatic rings, that is to say with cycloalkyl, heterocyclyl, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. It is preferred for the heteroaryl radical to be selected from the group comprising benzo-furanyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzo-triazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl (furanyl), imidazolyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazolyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pyrazolyl, pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl (thiophenyl), triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl, pyridyl and thienyl are particularly preferred.

Within the scope of the invention, the expressions “C₁₋₄-alkyl- or C₁₋₈-alkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyl” mean that C₁₋₄-alkyl or C₁₋₈-alkyl and aryl or heteroaryl or heterocyclyl or cycloalkyl have the meanings defined above and the aryl or heteroaryl or heterocyclyl or cycloalkyl radical is bonded to the general structure of higher order via a C₁₋₄-alkyl or C₁₋₈-alkyl group. The alkyl chain can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted. C₁₋₄-Alkyl or C₁₋₈-alkyl is preferably selected from the group comprising —CH₂—, —CH₂—CH₂—, —CH(CH₃)—, —CH₂—CH₂—CH₂—, —CH(CH₃)—CH₂—, —CH(CH₂CH₃)—, —CH₂—(CH₂)₂—CH₂—, —CH(CH₃)—CH₂—CH₂—, —CH₂—CH(CH₃)—CH₂—, —CH(CH₃)—CH(CH₃)—, —CH(CH₂CH₃)—CH₂—, —C(CH₃)₂—CH₂—, —CH(CH₂CH₂CH₃)—, —C(CH₃)(CH₂CH₃)—, —CH₂—(CH₂)₃—CH₂—, —CH(CH₃)—CH₂—CH₂—CH₂—, —CH₂—CH(CH₃)—CH₂—CH₂—, —CH(CH₃)—CH₂—CH(CH₃)—, —CH(CH₃)—CH(CH₃)—CH₂—, —C(CH₃)₂—CH₂—CH₂—, —CH₂—C(CH₃)₂—CH₂—, —CH(CH₂CH₃)—CH₂—CH₂—, —CH₂—CH(CH₂CH₃)—CH₂—, —O(CH₃)₂—CH(CH₃)—, —CH(CH₂CH₃)—CH(CH₃)—, —C(CH₃)(CH₂CH₃)—CH₂—, —CH(CH₂CH₂CH₃)—CH₂—, —C(CH₂CH₂CH₃)—CH₂—, —CH(CH₂CH₂CH₂CH₃)—, —C(CH₃)(CH₂CH₂CH₃)—, —C(CH₂CH₃)₂—, —CH₂—(CH₂)₄—CH₂—, —CH═CH—, —CH═CH—CH₂—, —C(CH₃)═CH₂—, —CH═CH—CH₂—CH₂—, —CH₂—CH═CH—CH₂—, —CH═CH—CH═CH—, —C(CH₃)═CH—CH₂—, —CH═C(CH₃)—CH₂—, —C(CH₃)═C(CH₃)—, —C(CH₂CH₃)═CH—, —CH═CH—CH₂—CH₂—CH₂—, —CH₂—CH═CH₂—CH₂—CH₂—, —CH═CH═CH—CH₂—CH₂—, —CH═CH₂—CH—CH═CH₂—, —C≡O—, —C≡C—CH₂—, —C≡C—CH₂—CH₂—, —C≡C—CH(CH₃)—, —CH₂—C≡C—CH₂—, —C≡C—C≡C—, —C≡C—C(CH₃)₂—, —C≡C—CH₂—CH₂—CH₂—, —CH₂—C═C—CH₂—CH₂—, —C≡C—C≡C—CH₂— and —C═C—CH₂—C≡C—.

Within the scope of the invention, the expressions “C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, heterocyclyl or cycloalkyl” mean that C₂₋₈-heteroalkyl and aryl or heteroaryl or heterocyclyl or cycloalkyl have the meanings defined above and the aryl or heteroaryl or heterocyclyl or cycloalkyl radical is bonded to the general structure of higher order via a C₂₋₈-heteroalkyl group. The heteroalkyl chain can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted. If a terminal carbon atom of the C₂₋₈-heteroalkyl group has been replaced by a heteroatom or heteroatom group, then the bonding of a heteroaryl or heterocyclyl to the heteroatom or heteroatom group of the C₂₋₈-heteroalkyl always takes place via a carbon atom of the heteroaryl or heterocyclyl. The terminal carbon atom is understood as being the carbon atom within the C₂₋₈-heteroalkyl that is furthest in the chain from the general structure of higher order. If the terminal carbon atom of a C₂₋₈-heteroalkyl has been replaced, for example, by an N(CH₃) group, that group is located within the C₂₋₈-heteroalkyl furthest from the general structure of higher order and is bonded to the aryl or heteroaryl or heterocyclyl or cycloalkyl radical. C₂₋₈-Heteroalkyl is preferably selected from the group comprising —CH₂—NH—, —CH₂—N(CH₃)—, —CH₂—O—, —CH₂—CH₂—NH—, —CH₂—CH₂—N(CH₃)—, —CH₂—CH₂—O—, —CH₂—CH₂—CH₂—NH—, —CH₂—CH₂—CH₂—N(CH₃)—, —CH₂—CH₂—CH₂—O—, —CH₂—O—CH₂—, —CH₂—CH₂—O—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—, —CH₂—CH₂—O—CH₂—CH₂—O—CH₂—, —CH═CH—O—CH₂—, —CH═CH—O—CH₂—CH₂—, ═CH—O—CH₂—, ═CH—O—CH₂—CH₂—, ═CH—CH₂—O—CH₂—CH₂—, ═CH—CH₂—O—CH₂—, —CH₂—NH—CH₂—, —CH₂—CH₂—NH—CH₂—, —CH₂—CH₂—NH—CH₂—CH₂—, —CH₂—CH₂—NH—CH₂—CH₂—NH—CH₂, —CH═CH—NH—CH₂—, —CH═CH—NH—CH₂—CH₂—, —CH═CH—N(CH₃)—CH₂—CH₂—, ═CH—NH—CH₂—, ═CH—NH—CH₂—CH₂—, ═CH—CH₂—NH—CH₂—CH₂—, ═CH—CH₂—NH—CH₂—, —CH₂—N(CH₃)—CH₂—, —CH₂—CH₂—N(CH₃)—CH₂—, —CH₂—CH₂—N(CH₃)—CH₂—CH₂—, —CH₂—CH₂—N(CH₃)—CH₂—CH₂—N(CH₃)—CH₂—, CH₂—CH₂—NH—CH₂—CH₂—O—CH₂—, CH₂—CH₂—O—CH₂—CH₂—NH—CH₂—, CH₂—CH₂—N(CH₃)—CH₂—CH₂—O—CH₂—, CH₂—CH₂—O—CH₂—CH₂—N(CH₃)—CH₂—, CH₂—NH—CH₂—O—CH₂—, CH₂—O—CH₂—NH—CH₂—, CH₂—N(CH₃)—CH₂—O—CH₂—, CH₂—O—CH₂—N(CH₃)—CH₂—, —CH═CH—N(CH₃)—CH₂—, ═CH—N(CH₃)—CH₂—, ═CH—N(CH₃)—CH₂—CH₂—, ═CH—CH₂—N(CH₃)—CH₂—CH₂— and ═CH—CH₂—N(CH₃)—CH₂—.

In connection with “alkyl”, “heteroalkyl”, “heterocyclyl” and “cycloalkyl”, the expression “mono- or poly-substituted” is understood as meaning within the scope of this invention the substitution of one or more hydrogen atoms one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F; Cl; Br; I; NO₂; CF₃; CN; ═O; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; 0-(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; and S(═O)₂—NH—C₁₋₈-heteroaryl; wherein polysubstituted radicals are to be understood as being radicals that are substituted several times, for example two, three or four times, either on different atoms or on the same atom, for example three times on the same carbon atom, as in the case of CF₃ or CH₂CF₃, or at different places, as in the case of CH(OH)—CH═CH—CHCl₂. A substituent can itself optionally be mono- or poly-substituted. Polysubstitution can take place with the same or with different substituents.

Preferred “alkyl”, “heteroalkyl”, “heterocyclyl” and “cycloalkyl” substituents are selected from the group comprising F; Cl; Br; I; NO₂; CH₂CF₃; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; phenyl; naphthyl; pyridyl; thienyl; furyl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl, cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; CO₂H; C(═O)O—C₁₋₈-alkyl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; OH; ═O; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-phenyl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-O(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-phenyl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂—NH—C₁₋₈-alkyl.

In connection with “aryl” and “heteroaryl”, “mono- or poly-substituted” is understood within the scope of this invention as meaning the substitution of one or more hydrogen atoms of the ring system one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F; Cl; Br; I; NO₂; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-O(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; NH—O(═O)-aryl; NH—C(═O)-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; S(═O)₂—NH—C₁₋₈-heteroaryl; on one atom or optionally on different atoms, wherein a substituent can itself optionally be mono- or poly-substituted. Polysubstitution is carried out with the same or with different substituents.

Preferred “aryl” and “heteroaryl” substituents are F; Cl; Br; I; NO₂; CH₂CF₃; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; phenyl; naphthyl; pyridyl; thienyl; furyl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged phenyl, naphthyl, pyridyl, thienyl, furyl, C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; CO₂H; C(═O)O—C₁₋₈-alkyl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-phenyl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; NH₂, NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-O(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-phenyl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂—NH—C₁₋₈-alkyl.

The compounds according to the invention are defined by substituents, for example by R¹, R² and R³ (1st generation substituents), which are themselves optionally substituted (2nd generation substituents). Depending on the definition, these substituents of the substituents can in turn themselves be substituted (3rd generation substituents). If, for example, R¹=aryl (1st generation substituent), aryl can itself be substituted, for example by C₁₋₈-alkyl (2nd generation substituent). This yields the functional group aryl-C₁₋₈-alkyl. C₁₋₈-Alkyl can then in turn itself be substituted, for example by Cl (3rd generation substituent). Overall, this then yields the functional group aryl-C₁₋₈-alkyl-Cl.

In a preferred embodiment, however, the 3rd generation substituents cannot themselves be substituted, that is to say there are no 4th generation substituents.

In another preferred embodiment, the 2nd generation substituents cannot themselves be substituted, that is to say there are not even any 3rd generation substituents. In other words, in this embodiment, for example in the case of the general formula (1), the functional groups for R¹ to R¹³ can in each case optionally be substituted, but the substituents in each case cannot themselves be substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl radical, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted. Both these aryl or heteroaryl radicals and the aromatic ring systems so formed can optionally be fused with C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, that is to say with a C₃₋₁₀-cycloalkyl such as cyclopentyl or with a heterocyclyl such as morpholinyl, it being possible for the C₃₋₁₀-cycloalkyl or heterocyclyl radicals so fused to be unsubstituted or mono- or poly-substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry a C₃₋₁₀-cycloalkyl or heterocyclyl radical, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example a C₃₋₁₀-cycloalkyl or heterocyclyl, in each case unsubstituted or mono- or poly-substituted. Both these C₃₋₁₀-cycloalkyl or heterocyclyl radicals and the aliphatic ring systems formed can optionally be fused with aryl or heteroaryl, that is to say with an aryl such as phenyl or with a heteroaryl such as pyridyl, it being possible for the aryl or heteroaryl radicals so fused to be unsubstituted or mono- or poly-substituted.

Within the scope of the present invention, the symbol

used in formulae denotes a linking of a corresponding radical to the general structure of higher order.

The expression “salt formed with a physiologically acceptable acid” is understood within the scope of this invention as meaning salts of the active ingredient in question with inorganic or organic acids that are physiologically acceptable—in particular when used in humans and/or mammals. The hydrochloride is particularly preferred. Examples of physiologically acceptable acids are: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, maleic acid, lactic acid, citric acid, glutamic acid, saccharinic acid, monomethylsebacic acid, 5-oxo-proline, hexane-1-sulfonic acid, nicotinic acid, 2-, 3- or 4-aminobenzoic acid, 2,4,6-trimethyl-benzoic acid, α-liponic acid, acetylglycine, hippuric acid, phosphoric acid and/or aspartic acid. Citric acid and hydrochloric acid are particularly preferred.

Physiologically acceptable salts with cations or bases are salts of the compound in question—in the form of the anion with at least one, preferably inorganic cation—that are physiologically acceptable—in particular when used in humans and/or mammals. Particular preference is given to the salts of the alkali and alkaline earth metals but also to ammonium salts, but in particular to (mono-) or (di-)sodium, (mono-) or (di-)potassium, magnesium or calcium salts.

In preferred embodiments of the compounds of the general formula (1) according to the invention

A¹ represents S and A² represents CR¹²R¹³, O, S or S(═O)₂, preferably CR¹²R¹³, S or S(═O)₂, particularly preferably CR¹²R¹³.

Further preferred embodiments of the compounds of the general formula (1) according to the invention have the general formula (1a), (1b), (1c), (1d), (1e) or (1f):

Compounds of the general formulae (1a), (1 b) and (1c) are most particularly preferred.

Compounds of the general formula (1a) are especially preferred.

In a further preferred embodiment the radical R¹ represents

C₁₋₁₀-alkyl or C₂₋₁₀-heteroalkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CF₃, CN, OH, ═O, C(═O)—OH, OCF₃, NH₂, S(═O)₂OH, SH, SCF₃, C₁₋₈-alkyl, O—C₁₋₈-alkyl, S—C₁₋₈-alkyl, NH—C₁₋₈-alkyl, N(C₁₋₈-alkyl)₂, C₃₋₁₀-cycloalkyl and heterocyclyl, wherein the above alkyl radicals can in each case be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and wherein C₃₋₁₀-cycloalkyl or heterocyclyl can in each case be saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, C₁₋₈-alkyl, OH, ═O, O—-C₁₋₈-alkyl, OCF₃, NH₂, NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂; C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH, C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH;

-   -   wherein the alkyl or heteroalkyl chain can in each case be         branched or unbranched, saturated or unsaturated, unsubstituted         or mono- or poly-substituted by one or more substituents each         selected independently of one another from the group consisting         of F, Cl, Br, I, NO₂, CF₃, CN, OH, ═O, C(═O)—OH, OCF₃, NH₂,         S(═O)₂OH, SH, SCF₃, C₁₋₈-alkyl, 0-C₁₋₈-alkyl, S—C₁₋₈-alkyl,         NH—C₁₋₈-alkyl, N(C₁₋₈-alkyl)₂, C₃₋₁₀-cycloalkyl and         heterocyclyl, wherein the above alkyl radicals can in each case         be saturated or unsaturated, branched or unbranched,         unsubstituted or mono- or poly-substituted by one or more         substituents each selected independently of one another from the         group consisting of F, Cl, Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and         wherein C₃₋₁₀-cyclo-alkyl or heterocyclyl can in each case be         saturated or unsaturated, unsubstituted or mono- or         poly-substituted by one or more substituents each selected         independently of one another from the group consisting of F, Cl,         Br, I, C₁₋₈-alkyl, OH, ═O, O—-C₁₋₈-alkyl, OCF₃, NH₂,         NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂;         or C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl or heteroaryl,         in each case unsubstituted or mono- or poly-substituted by one         or more substituents each selected independently of one another         from the group consisting of F, Cl, Br, I, NO₂, CN, OH,         O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂,         NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃,         S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl,         phenyl, pyridyl, thienyl can in each case be unsubstituted or         mono- or poly-substituted by one or more substituents selected         independently of one another from the group consisting of F, Cl,         Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH,         CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃         and S(═O)₂OH;     -   wherein the alkyl or heteroalkyl chain can in each case be         branched or unbranched, saturated or unsaturated, unsubstituted         or mono- or poly-substituted by one or more substituents each         selected independently of one another from the group consisting         of F, Cl, Br, I, NO₂, CF₃, CN, OH, ═O, C(═O)—OH, OCF₃, NH₂,         S(═O)₂OH, SH, SCF₃, C₁₋₈-alkyl, 0-C₁₋₈-alkyl, S—C₁₋₈-alkyl,         NH—C₁₋₈-alkyl, N(C₁₋₈-alkyl)₂, C₃₋₁₀-cycloalkyl and         heterocyclyl, wherein the above alkyl radicals can in each case         be saturated or unsaturated, branched or unbranched,         unsubstituted or mono- or poly-substituted by one or more         substituents each selected independently of one another from the         group consisting of F, Cl, Br, I, O—C₁₋₈-alkyl, OH and OCF₃, and         wherein C₃₋₁₀-cyclo-alkyl or heterocyclyl can in each case be         saturated or unsaturated, unsubstituted or mono- or         poly-substituted by one or more substituents each selected         independently of one another from the group consisting of F, Cl,         Br, I, C₁₋₈-alkyl, OH, ═O, O—C₁₋₈-alkyl, OCF₃, NH₂,         NH—C₁₋₈-alkyl and N(C₁₋₈-alkyl)₂.

In a further preferred embodiment the substituent R¹ represents the following partial structure (T1)

wherein

-   R^(14a) and R^(14b) each independently of the other represents H; F;     Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; NH₂; C₁₋₄-alkyl, 0-C₁₋₄-alkyl,     NH—C₁₋₄-alkyl, N(C₁₋₄-alkyl)₂, in each case saturated or     unsaturated, branched or unbranched, unsubstituted or mono- or     poly-substituted by one or more substituents each selected     independently of one another from the group consisting of F, Cl, Br,     I, O—C₁₋₄-alkyl, OH and OCF₃; C₃₋₁₀-cycloalkyl or heterocyclyl, in     each case saturated or unsaturated, unsubstituted or mono- or     poly-substituted by one or more substituents each selected     independently of one another from the group consisting of F, Cl, Br,     I, C₁₋₄-alkyl, OH, ═O, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and     N(C₁₋₄-alkyl)₂; -   m represents 0, 1, 2 or 3; -   Y represents O or NR¹⁵,     -   wherein R¹⁵ represents H; C₁₋₄-alkyl, saturated or unsaturated,         branched or unbranched, unsubstituted or mono- or         poly-substituted by one or more substituents each selected         independently of one another from the group consisting of F, Cl,         Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl         and N(C₁₋₄-alkyl)₂; or represents C₃₋₁₀-cycloalkyl, saturated or         unsaturated, unsubstituted or mono- or poly-substituted by one         or more substituents each selected independently of one another         from the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH,         O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and N(C₁₋₄-alkyl)₂; -   n represents 0 or 1, -   B represents C₁₋₈-alkyl, saturated or unsaturated, branched or     unbranched, unsubstituted or mono- or poly-substituted by one or     more substituents each selected independently of one another from     the group consisting of F, Cl, Br, I, NO₂, CN, OH, ═O,     O—-C₁₋₄-alkyl, OCF₃, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl),     N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH;     C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or     unsaturated, unsubstituted or mono- or poly-substituted by one or     more substituents each selected independently of one another from     the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl,     OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl),     N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl,     pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in     each case be unsubstituted or mono- or poly-substituted by one or     more substituents selected independently of one another from the     group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃,     C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH,     S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH; aryl or heteroaryl, in each case     unsubstituted or mono- or poly-substituted by one or more     substituents each selected independently of one another from the     group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃,     C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH,     S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl,     wherein benzyl, phenyl, pyridyl, thienyl can in each case be     unsubstituted or mono- or poly-substituted by one or more     substituents selected independently of one another from the group     consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃,     C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH,     S—C₁₋₈-alkyl, SCF₃ and S(═O)₂OH.

Preferably,

-   R^(14a) and R^(14b) each independently of the other represents H; F;     Cl; Br; I; NO₂; CF₃; CH₂CF₃; CN; OH; OCF₃, NH₂; C₁₋₄-alkyl,     O—C₁₋₄-alkyl, O—C₁₋₄-alkyl-OH, O—C₁₋₄-alkyl-OCH₃, NH—C₁₋₄-alkyl,     N(C₁₋₄-alkyl)₂, in each case saturated or unsaturated, branched or     unbranched, unsubstituted; C₃₋₁₀-cycloalkyl, saturated or     unsaturated, unsubstituted or mono- or poly-substituted by one or     more substituents each selected independently of one another from     the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl; -   m represents 0, 1, 2 or 3; -   Y represents O or NR¹⁵;     -   wherein R¹⁵ represents H; C₁₋₄-alkyl, saturated or unsaturated,         unsubstituted; or represents C₃₋₁₀-cycloalkyl, saturated or         unsaturated, unsubstituted; -   n represents 0 or 1; -   B represents C₁₋₈-alkyl, saturated or unsaturated, branched or     unbranched, unsubstituted or mono- or poly-substituted by one or     more substituents each selected independently of one another from     the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl,     OCF₃, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SCF₃;     C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or     unsaturated, unsubstituted or mono- or poly-substituted by one or     more substituents each selected independently of one another from     the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl,     OCF₃, C₁₋₄-alkyl, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SCF₃;     aryl or heteroaryl, in each case unsubstituted or mono- or     poly-substituted by one or more substituents each selected     independently of one another from the group consisting of F, Cl, Br,     I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,     NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, S(═O)₂OH,     benzyl, phenyl and pyridyl, wherein benzyl, phenyl or pyridyl are in     each case unsubstituted or mono- or poly-substituted by one or more     substituents each selected independently of one another from the     group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃,     C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH,     S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH.

Particularly preferably, R^(14a) and R^(14b) each independently of the other represents H; F; CI; Br; I; NO₂; CF₃; CN; methyl; ethyl; n-propyl; isopropyl; cyclopropyl; n-butyl; sec-butyl; tert-butyl; CH₂CF₃; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; OCF₃; NH₂; NH-methyl; N(methyl)_(2i) NH-ethyl; N(ethyl)_(2i) or N(methyl)(ethyl);

-   m represents 0, 1 or 2; -   n represents 0; and -   B represents C₁₋₄-alkyl, saturated, branched or unbranched,     unsubstituted or mono- or poly-substituted by one or more     substituents each selected independently of one another from the     group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, OCF₃ and CF₃;     C₃₋₁₀-cycloalkyl, saturated, unsubstituted; phenyl, naphthyl,     pyridyl, thienyl, in each case unsubstituted or mono- or di- or     tri-substituted by one, two or three substituents each selected     independently of one another from the group consisting of F, Cl, Br,     I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,     NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, S(═O)₂OH.

Most particularly preferably, R^(14a) and R^(14b) each independently of the other represents H; F; Cl; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH;

-   m represents 0, 1 or 2; -   n represents 0; and -   B represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl;     tert-butyl;

cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case unsubstituted or mono-, di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH.

For n=0, the partial structure (T-1) for R¹ yields the partial structure (T1-1):

In a preferred embodiment for n=0, R^(14a) and R^(14b) each independently of the other represents H; F; Cl; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH.

In a preferred embodiment for m=0, B represents phenyl, pyridyl or thienyl, mono- or di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, S(═O)₂OH.

In a preferred embodiment for m=1 or 2, B represents cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl.

In a preferred embodiment for m=0, 1 or 2, B represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl or tert-butyl.

A further particularly preferred embodiment of the compounds of the general formula (1) according to the invention has the general formula (2):

In a further preferred embodiment, the radicals R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; CH₂—O-methyl; CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl or S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, ═O and O—C₁₋₄-alkyl; C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted; NR^(a)R^(b), wherein R^(a) and R^(b) each independently of the other represents H or C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of OH, ═O and O—C₁₋₄-alkyl, or R^(a) and R^(b), together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by C₁₋₄-alkyl.

Preferably, the radicals R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; ethyl; n-propyl; isopropyl; butyl; sec-butyl; tert-butyl; CH₂CF₃; O-methyl; O-ethyl; O-n-propyl; O-isopropyl; O-butyl; O-sec-butyl; O-tert-butyl; O—(CH₂)₂—O-methyl; 0-(CH₂)₂—OH; O—(C═O)-methyl; O—(C═O)-ethyl; S-methyl; S-ethyl; cyclopropyl; cyclobutyl; NR^(a)R^(b), wherein R^(a) and R^(b) each independently of the other is selected from the group consisting of H, methyl, ethyl, (CH₂)₂—O-methyl, (CH₂)₂—OH, (C═O)-methyl, (C═O)-ethyl, or R^(a) and R^(b), together with the nitrogen atom joining them, form a pyrrolidinyl, piperidinyl, 4-methyl-piperazinyl or morpholinyl.

Particularly preferably, the radicals R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; CN; CF₃; O-methyl; OCF₃; S-methyl; SCF₃, pyrrolidinyl, N(methyl)₂.

Most particularly preferably, the radicals R², R³ and R⁴ each independently of the others represents H; F; Cl; methyl; ethyl; O-methyl; CF₃; in particular H.

In a further preferred embodiment, the radicals R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; C₁₋₆-alkyl; O—C₁₋₆-alkyl or S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH and O—C₁₋₄-alkyl; C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, ═O and O—C₁₋₄-alkyl;

or R⁵ and R⁶ or R⁷ and R⁸ or R¹⁰ and R¹¹ or R¹² and R¹³ or R⁵ and R¹¹ or R⁵ and R⁷ or R⁵ and R¹³ or R⁷ and R¹³ or R⁷ and R¹¹ or R¹¹ and R¹³, together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl or piperidinyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, ═O and O—C₁₋₄-alkyl; wherein the remaining substituents R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ in each case have the meaning given above.

Preferably, the radicals R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-methyl; S-ethyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl;

or R⁵ and R⁶ or R⁷ and R⁸ or R¹⁰ and R¹¹ or R¹² and R¹³ or R⁵ and R¹¹ or R⁵ and R⁷ or R⁵ and R¹³ or R⁷ and R¹³ or R⁷ and R¹¹ or R¹¹ and R¹³, together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; wherein the remaining substituents R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ in each case have the meaning given above.

Particularly preferably, the radicals R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; O-methyl; S-methyl; or

R⁵ and R⁷ form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl ring substituted as desired by H, F, Cl, Me, Et, OMe, preferably an unsubstituted cyclopentyl or cyclohexyl ring.

Most particularly preferably, the radicals R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents F; Cl; H; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; in particular F; H; methyl; or ethyl.

In particular, the radicals R¹² and R¹³ each independently of the other represents H, F or methyl.

In a further preferred embodiment, the radical R⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, ON, OH, ═O, O—-C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, ON, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl and SCF₃; or represents CR^(c)R^(d), wherein R^(c) and R^(d) each independently of the other denotes C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, CF₃, OCF₃ and SCF₃.

Preferably, R⁹ represents C₃₋₇-cycloalkyl, saturated or unsaturated, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, piperidinyl, morpholinyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃; phenyl, naphthyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, ON, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃; or represents CR^(c)R^(d), wherein R^(c) and R^(d) each independently of the other denotes C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH and O—C₁₋₄-alkyl.

Particularly preferably, the radical R⁹ is selected from the group consisting of phenyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.

Most particularly preferably, R⁹ represents phenyl, pyridyl and thienyl, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, O-n-propyl, O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF₃, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.

In particular, R⁹ represents phenyl, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, OCF₃, CF₃ and SCF₃.

In a further, particularly preferred embodiment

A¹ represents S; A² represents CR¹²R¹³; R¹ represents the partial structure (T1-1)

wherein

-   -   R^(14a) and R^(14b) each independently of the other represents         H; F; Cl; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl;         sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; or         O—(CH₂)₂—OH;     -   m represents 0, 1 or 2;     -   B represents methyl; ethyl; n-propyl; isopropyl; n-butyl;         sec-butyl; tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl;         cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl;         bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case         unsubstituted or mono-, di- or tri-substituted by one, two or         three substituents each selected independently of one another         from the group consisting of F, Cl, Br, I, NO₂, CN, OH,         O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂,         NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and         S(═O)₂OH;         R², R³ and R⁴ each independently of the others represents H; F;         Cl; Br; I; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; CN;         CF₃; O-methyl; OCF₃; S-methyl; SCF₃;         R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the         others represents H; F; Cl; Br; I; CN; CF₃; OCF₃; SCF₃; methyl;         ethyl; n-propyl, isopropyl; cyclopropyl; O-methyl; S-methyl; and         R⁹ represents cyclopentyl or cyclohexyl, in each case         unsubstituted or mono- or poly-substituted by one or more         substituents each selected independently of one another from the         group consisting of F, Cl, Br, I, OH, O-methyl, OCF₃, methyl,         ethyl and CF₃; phenyl, unsubstituted or mono- or         poly-substituted by one or more substituents each selected         independently of one another from the group consisting of F, Cl,         Br, I, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl,         sec-butyl, tert-butyl, O-methyl, O-ethyl, O-n-propyl,         O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF₃, CF₃,         SH, S—C₁₋₄-alkyl and SCF₃; or represents methyl, ethyl,         n-propyl, isopropyl.

Particular preference is given to compounds from the group

-   1     2-(3-Phenyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   2     2-(3-Cyclohexyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   3     2-[(3-Oxo-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   4     N-(Thiophen-2-yl-methyl)-2-[2-[3-(trifluoromethyl)-phenoxy]-ethylsulfanyl]-pyridine-3-carboxylic     acid amide; -   5     2-(4-Methyl-pentylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   7 2-(4-Phenyl-butyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   8     2-[3-(Benzenesulfonyl)-propyl]-N-(cyclohexyl-methyl)-pyridine-3-carboxylic     acid amide; -   9 N-(Cyclohexyl-methyl)-2-(4-phenyl-butyl)-pyridine-3-carboxylic     acid amide; -   10     2-[3-(Benzenesulfonyl)-propyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   12     N-(Thiophen-2-yl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic     acid amide; -   13     N-(Thiophen-2-yl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfanyl]-propyl]-pyridine-3-carboxylic     acid amide; -   16     2-(2-Phenylsulfanyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   17     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   18     N-(Thiophen-2-yl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide; -   19     2-[2-[(4-Fluorophenyl)sulfanyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   20     N-(Thiophen-2-yl-methyl)-2-[2-[[3-(trifluoromethyl)phenyl]sulfanyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide; -   21     N-(Thiophen-2-yl-methyl)-2-[4-[3-(trifluoromethyl)-phenyl]-butyl]-pyridine-3-carboxylic     acid amide; -   22     2-[4-(4-Fluorophenyl)-butyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   23     2-(3-Phenylsulfanyl-propyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   24     2-[(1-Methyl-2-phenylsulfanyl-ethyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide; -   25     N-(Cycloheptyl-methyl)-2-[4-[3-(trifluoromethyl)phenyl]-butyl]-pyridine-3-carboxylic     acid amide -   26     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[4-[3-(trifluoromethyl)phenyl]-butyl]-pyridine-3-carboxylic     acid amide -   27     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   28     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(4-methyl-pentylsulfanyl)-pyridine-3-carboxylic     acid amide -   29     N-(Cycloheptyl-methyl)-2-[3-[(4-fluorophenyl)sulfanyl]-propyl]-pyridine-3-carboxylic     acid amide -   30     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[(4-fluorophenyl)sulfanyl]-propyl]-pyridine-3-carboxylic     acid amide -   31     N-(Cycloheptyl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic     acid amide -   32     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic     acid amide -   33     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3-phenyl-propylsulfanyl)-pyridine-3-carboxylic     acid amide -   34     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[4-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   35     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-chlorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   36     N-[(3,5-Difluoro-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   37     N-[(5-Chloro-thiophen-2-yl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   38     N-[(2,2-Dimethyl-cyclopropyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   39     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   40     N-(Cyclohexyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   41     N-(Cycloheptyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   43     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-3-oxo-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   44     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[(3-oxo-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic     acid amide -   45     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(hexylsulfanyl)-pyridine-3-carboxylic     acid amide -   46     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(2-phenoxy-ethylsulfanyl)-pyridine-3-carboxylic     acid amide -   47     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2-[3-(trifluoromethyl)-phenoxy]-ethylsulfanyl]-pyridine-3-carboxylic     acid amide -   48     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3,3,3-trifluoro-propyl)-pyridine-3-carboxylic     acid amide -   49     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2-(4-fluoro-phenoxy)-ethylsulfanyl]-pyridine-3-carboxylic     acid amide -   52     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3-naphthalen-1-yl-propylsulfanyl)-pyridine-3-carboxylic     acid amide -   53     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-fluoro-4-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   54     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[4-fluoro-3-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   55     N-(Cyclooctyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   56     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-methoxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   57     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-methoxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   59     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(trifluoromethyl)phenyl]-methyl]-pyridine-3-carboxylic     acid amide -   60     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,4-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   61     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,5-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   62     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(2,4-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   63     N-[(2-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   64     N-[(3-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   65     N-[(4-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   66     N-Benzyl-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   67     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[(1-methyl-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic     acid amide -   68     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,4,5-trifluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   69     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-fluoro-5-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   70     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-methoxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   71     N-[(3,4-Difluoro-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   72     N-(2,3-Dihydro-benzofuran-5-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   73     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-hydroxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   74     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   75     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-2-methyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   76     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(2-methoxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   77     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-methoxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   78     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-phenethyl-pyridine-3-carboxylic     acid amide -   79     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[4-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic     acid amide -   80     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic     acid amide -   81     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-3-yl-ethyl)-pyridine-3-carboxylic     acid amide -   82     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-2-yl-ethyl)-pyridine-3-carboxylic     acid amide -   83     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(2-hydroxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   84     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-hydroxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   85     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(m-tolyl)-ethyl]-pyridine-3-carboxylic     acid amide -   86     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(o-tolyl)-ethyl]-pyridine-3-carboxylic     acid amide -   87     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic     acid amide -   88     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-hydroxyphenyl)-methyl]-pyridine-3-carboxylic     acid amide -   89     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-4-yl-ethyl)-pyridine-3-carboxylic     acid amide -   90     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(p-tolyl)-ethyl]-pyridine-3-carboxylic     acid amide -   91     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-butylsulfanyl]-pyridine-3-carboxylic     acid amide -   92     N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(2,4,5-trifluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   93     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-2-yl-propyl)-pyridine-3-carboxylic     acid amide -   94     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-3-yl-propyl)-pyridine-3-carboxylic     acid amide -   95     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-4-yl-propyl)-pyridine-3-carboxylic     acid amide -   96     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-propyl-pyridine-3-carboxylic     acid amide -   97     N-Butyl-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   98     2-(3-Pyridin-3-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   99     2-[3-(p-Tolyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   100     2-(4-Phenyl-butylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   101     2-(3-Pyridin-4-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   102     2-(3-Naphthalen-2-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   103     2-[3-(m-Tolyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   104     N-(Thiophen-2-yl-methyl)-2-(3-thiophen-2-yl-propylsulfanyl)-pyridine-3-carboxylic     acid amide -   105     2-[(1-Methyl-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   106     N-(Thiophen-2-yl-methyl)-2-(3-thiophen-3-yl-propylsulfanyl)-pyridine-3-carboxylic     acid amide -   107     2-[[1-Methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   108     2-[(2-Benzyl-cyclohexyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   109     2-[3-[3-Methyl-5-(trifluoromethyl)-phenyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   110     2-[4-(3,4-Difluoro-phenyl)-butylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   111     2-(3-Pyridin-2-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   113     2-[3-[4-Methyl-3-(trifluoromethyl)-phenyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   114     2-[(3-Phenyl-cyclohexyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   116     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3,3-dimethyl-butyl)-pyridine-3-carboxylic     acid amide -   117     N-(Cycloheptyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   118     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   119     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(1,2,3,4-tetrahydro-naphthalen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   120     N-(2,3-Dihydro-1H-inden-2-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   121     N-(1,3-Benzodioxol-5-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   122     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-phenyl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   123     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-methyl-cyclohexyl)-methyl]-pyridine-3-carboxylic     acid amide -   124     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic     acid amide -   125     N-(3,3-Dimethyl-2-oxo-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   127     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(pyridin-3-yl-methyl)-pyridine-3-carboxylic     acid amide -   128     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(pyridin-4-yl-methyl)-pyridine-3-carboxylic     acid amide -   129     3-[[[2-[3-(4-Fluorophenyl)-propylsulfanyl]-pyridine-3-carbonyl]amino]-methyl]-benzoic     acid methyl ester -   130     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(2-methoxyphenyl)-propyl]-pyridine-3-carboxylic     acid amide -   132     N-[(4-Fluorophenyl)-methyl]-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   133     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic     acid amide -   134     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(tetrahydro-pyran-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   135     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-pyrazol-1-yl)-propyl]-pyridine-3-carboxylic     acid amide -   136     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(naphthalen-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   137     N-(2,3-Dihydro-[1,4]benzodioxin-6-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   138     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-morpholin-4-yl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   139     N-(2,3-Dihydro-benzofuran-6-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   140     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(1H-pyrazol-1-yl)-phenyl]-methyl]-pyridine-3-carboxylic     acid amide -   141     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-[1,2,3]triazol-1-yl)-propyl]-pyridine-3-carboxylic     acid amide -   142     N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   144     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiazol-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   145     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiazol-5-yl-methyl)-pyridine-3-carboxylic     acid amide -   146     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(oxazol-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   148     N-(3,3-Dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-4-methyl-pyridine-3-carboxylic     acid amide -   149     N-(3,3-Dimethyl-butyl)-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   150     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(quinolin-7-yl-methyl)-pyridine-3-carboxylic     acid amide -   151     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-2-yl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   152     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-3-yl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   153     N-(3,3-Dimethyl-butyl)-2-[[(1R)-1-methyl-3-phenyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   154     N-(3,3-Dimethyl-butyl)-2-[[(1S)-1-methyl-3-phenyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   155     2-[(2-Benzyl-cyclopentyl)sulfanyl]-(3,3-dimethyl-butyl)-pyridine-3-carboxylic     acid amide -   156     N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   157     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-[1,2,4]triazol-1-yl)-propyl]-pyridine-3-carboxylic     acid amide -   158     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-([1,3,4]oxadiazol-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   159     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-4-yl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   160     N-[[4-(Cyclopropyl-methyl)-3,4-dihydro-2H-[1,4]benzoxazin-6-yl]-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   161     N-[(4-Ethyl-3,4-dihydro-2H-[1,4]benzoxazin-6-yl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   162     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-methyl-3,4-dihydro-2H-[1,4]benzoxazin-6-yl)-methyl]-pyridine-3-carboxylic     acid amide -   163     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-methyl-3-phenyl-butyl)-pyridine-3-carboxylic     acid amide -   164     N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   165     2-[[3,3-Difluoro-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic     acid amide -   166     2-[[3,3-Difluoro-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-(3,3-dimethyl-butyl)-pyridine-3-carboxylic     acid amide -   168     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(3-fluorophenyl)-methyl]-pyridine-3-carboxylic     acid amide -   170     N-Butyl-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   171     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-ethyl)-pyridine-3-carboxylic     acid amide -   172     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-methoxy-ethyl)-pyridine-3-carboxylic     acid amide -   173     N-[(4-Fluoro-2-hydroxy-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   174     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(furan-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   175     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(5-methyl-furan-2-yl)-methyl]-pyridine-3-carboxylic     acid amide -   176     N-[(4-Fluorophenyl)-methyl]-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   177     2-[[3-(4-Fluorophenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic     acid amide -   178     N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   179     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-furan-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   180     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   181     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(tetrahydro-furan-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   182     2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-methoxy-3,3-dimethyl-butyl)-pyridine-3-carboxylic     acid amide -   183     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(m-tolyl-methyl)-pyridine-3-carboxylic     acid amide -   184     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(3,5-dimethyl-phenyl)-methyl]-pyridine-3-carboxylic     acid amide -   185     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-propyl-pyridine-3-carboxylic     acid amide -   186     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-hexyl-pyridine-3-carboxylic     acid amide -   187     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-furan-3-yl-methyl)-pyridine-3-carboxylic     acid amide -   188     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-3-yl-methyl)-pyridine-3-carboxylic     acid amide -   189     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-4-yl-methyl)-pyridine-3-carboxylic     acid amide -   190     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(furan-2-yl-methyl)-pyridine-3-carboxylic     acid amide -   191     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(5-methyl-furan-2-yl)-methyl]-pyridine-3-carboxylic     acid amide -   192     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-pentyl-pyridine-3-carboxylic     acid amide -   193     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methoxy-butyl)-pyridine-3-carboxylic     acid amide -   194     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-propyl)-pyridine-3-carboxylic     acid amide -   195     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-butyl)-pyridine-3-carboxylic     acid amide -   196     3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carbonyl]amino]-propionic     acid methyl ester -   197     3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carbonyl]amino]-propionic     acid -   198     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-dimethylaminoethyl)-pyridine-3-carboxylic     acid amide -   199     2-[[3-(3,4-Difluoro-phenyl)-1-methyl-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic     acid amide -   200     2-[[3-(3,4-Difluoro-phenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic     acid amide -   201     N-[(4-Fluorophenyl)-methyl]-2-[[3-(3-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   202     2-[[3-(3-Fluorophenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic     acid amide -   203     N-(3-Methyl-butyl)-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   204     2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic     acid amide -   205     N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   206     N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   207     N-[(4-Fluorophenyl)-methyl]-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   208     N-(3-Methyl-butyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic     acid amide -   209     2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic     acid amide -   210     N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(3,4-difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-pyridine-3-carboxylic     acid amide -   211     2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-hydroxy-ethyl)-pyridine-3-carboxylic     acid amide -   224     N-[(4-Fluoro-2-methoxy-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic     acid amide     or physiologically acceptable salts thereof.

The substituted nicotinamides according to the invention and in each case the corresponding acids, bases, salts and solvates are suitable as pharmaceutical active ingredients in medicaments.

The invention therefore further provides a medicament comprising at least one substituted nicotinamide of the general formula (1) according to the invention wherein the radicals R¹ to R¹³ have the meaning given above and, optionally, one or more pharmaceutically acceptable auxiliary substances.

In addition to at least one compound according to the invention, the medicaments according to the invention optionally comprise suitable additives and/or auxiliary substances, that is to say also carriers, fillers, solvents, diluents, colorings and/or binders, and can be administered as liquid medicament forms in the form of injection solutions, drops or juices, as semi-solid medicament forms in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols. The choice of auxiliary substances etc. and the amounts thereof to be used are dependent on whether the medicament is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes. Preparations in the form of tablets, dragées, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and sprays are suitable for parenteral, topical and inhalatory administration. Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents that promote penetration through the skin, are suitable percutaneous forms of administration. Forms of preparation for administration orally or percutaneously can release the compounds according to the invention in a delayed manner. The compounds according to the invention can also be administered in parenteral long-term depot forms such as, for example, implants or implanted pumps. In principle, other further active ingredients known to the person skilled in the art can be added to the medicaments according to the invention.

The medicaments according to the invention are suitable for influencing KCNQ2/3 channels and exert an agonistic or antagonistic action, in particular an agonistic action.

The medicaments according to the invention are preferably suitable for the treatment of disorders or diseases that are mediated at least in part by KCNQ2/3 channels.

The medicaments according to the invention are suitable preferably for the treatment of one or more diseases selected from the group consisting of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain and inflammatory pain; epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, dystonia-associated dyskinesias and/or urinary incontinence.

The medicaments according to the invention are suitable particularly preferably for the treatment of pain, most particularly preferably of chronic pain, neuropathic pain, inflammatory pain and muscular pain.

The medicaments according to the invention are also particularly preferably suitable for the treatment of epilepsy.

The invention further provides the use of at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, in the preparation of a medicament for the treatment of disorders or diseases that are mediated at least in part by KCNQ2/3 channels.

Preference is given to the use of at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, in the preparation of a medicament for the treatment of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain and inflammatory pain; epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, dystonia-associated dyskinesias and/or urinary incontinence.

Particular preference is given to the use of at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, in the preparation of a medicament for the treatment of pain, most particularly preferably chronic pain, neuropathic pain, inflammatory pain and muscular pain.

Particular preference is given also to the use of at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, in the preparation of a medicament for the treatment of epilepsy.

The invention further provides at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, for the treatment of disorders or diseases that are mediated at least in part by KCNQ2/3 channels.

The invention further provides at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, for the treatment of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain and inflammatory pain; epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, dystonia-associated dyskinesias and/or urinary incontinence.

Particular preference is given to at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, for the treatment of pain, most particularly preferably of chronic pain, neuropathic pain, inflammatory pain and muscular pain.

Particular preference is given also to at least one substituted nicotinamide according to the invention, and optionally one or more pharmaceutically acceptable auxiliary substances, for the treatment of epilepsy.

The effectiveness against pain can be shown, for example, in the Bennett or Chung model (Bennett, G. J. and Xie, Y. K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain 1988, 33(1), 87-107; Kim, S. H. and Chung, J. M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 1992, 50(3), 355-363). The effectiveness against epilepsy can be demonstrated, for example, in the DBA/2 mouse model (De Sarro et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 330-336).

The substituted nicotinamides according to the invention preferably have an EC₅₀ value of not more than 5 μM or not more than 3 μM, more preferably not more than 2 μM or not more than 1 μM, yet more preferably not more than 0.9 μM or not more than 0.6 μM, most preferably not more than 0.5 μM or not more than 0.3 μM and especially not more than 0.2 μM or not more than 0.1 μM. Methods for determining the EC₅₀ value are known to the person skilled in the art. The EC₅₀ value is preferably determined by fluorimetry, particularly preferably as described under “Pharmacological Experiments”.

The invention further provides processes for the preparation of the substituted nicotinamides according to the invention.

The chemicals and reaction components used in the reactions described hereinbelow are available commercially or can in each case be prepared by conventional methods known to the person skilled in the art.

General Reaction Schemes

In stage 1, acids of the general formula S-I are reacted with amines of the general formula RX-I in a reaction medium, preferably selected from the group consisting of ether, THF, MeCN, MeOH, EtOH, DMF and DCM, optionally in the presence of at least one coupling reagent, preferably selected from the group consisting of BOP, DCC, EDC, HATU, HBTU and HOAt, optionally in the presence of at least one inorganic base, preferably selected from the group consisting of potassium carbonate and caesium carbonate, or organic base, preferably selected from the group consisting of NEt₃, pyridine, DMAP and DIPEA, preferably at temperatures of from −70° C. to 100° C., optionally in the presence of microwave radiation, to give amides of the general formula S-II.

Alternatively, according to stage 1 the acids of the general formula S-I are first converted into the corresponding acid chlorides using reagents, for example selected from the group (COCl)₂, PCl₃, POCl₃ and SOCl₂, in a reaction medium, preferably selected from the group consisting of toluene, DMF, DCM and pyridine, at temperatures of from −70° C. to 100° C., optionally in the presence of microwave radiation, and then reacted with amines of the general formula RX-I in a reaction medium, preferably selected from the group consisting of ether, THF, MeCN, MeOH, EtOH, DMF and DCM, with or without the addition of at least one organic or inorganic base, for example NEt₃, DMAP, pyridine or DIPEA, optionally in the presence of at least one organic base, preferably selected from the group consisting of NEt₃, DMAP, pyridine and DIPEA, or inorganic base, at temperatures of preferably from −70° C. to 100° C., optionally in the presence of microwave radiation, to give amides of the general formula S-II.

In stage 2, compounds of the general formula S-II are reacted with compounds of the general formula RX-II, wherein LG represents a leaving group, preferably chlorine, bromine or iodine, in a reaction medium, preferably selected from the group consisting of acetone, ethanol, ether, methanol, THF, MeCN, toluene and DMF, optionally in the presence of at least one inorganic base, preferably selected from the group consisting of potassium carbonate, butyllithium, sodium hydride, sodium methylate or potassium tert-butylate, or organic base, preferably selected from the group consisting of NEt₃, pyridine, DMAP and DIPEA, preferably at temperatures of from −70° C. to 100° C., optionally in the presence of microwave radiation, to give compounds of the general formula (1).

In stage 3, acids of the general formula S-I are reacted with compounds of the general formula RX-II, wherein LG represents a leaving group, preferably chlorine, bromine or iodine, according to the process described in stage 2 to give compounds of the general formula S-III.

In stage 4, acids of the general formula S-III are reacted with amines of the general formula RX-I according to the process described in stage 1 to give compounds of the general formula (1).

In stage 5, acids of the general formula S-IV, wherein LG represents a leaving group, preferably a halide or methanesulfonate, particularly preferably chlorine, are reacted with amines of the general formula RX-I according to the processes described in stage 1 to give compounds of the general formula S-V.

In stage 6, compounds of the general formula S-V are reacted with compounds of the general formula RX-III, wherein A₁ represents O or S, in a reaction medium, preferably ether, THF, MeCN, toluene or DMF, optionally in the presence of at least one inorganic base, preferably selected from the group consisting of potassium carbonate, sodium hydride, sodium methylate or potassium tert-butylate, at temperatures of from −70° C. to 100° C., optionally in the presence of microwave radiation, to give compounds of the general formula (1).

In stage 7, compounds of the general formula S-VI, wherein LG represents a leaving group, preferably a halide or methanesulfonate, particularly preferably chlorine, and PG represents a protecting group, preferably methyl or ethyl, are reacted with compounds of the general formula RX-III, wherein A₁ represents S or O, according to the processes described in stage 6 to give compounds of the formula S-VII.

In stage 8, esters of the general formula S-VII, wherein PG represents a protecting group, preferably methyl or ethyl, are cleaved in a reaction medium, preferably selected from the group consisting of ethanol, methanol, MeCN, THF and water, or arbitrary mixtures thereof, optionally with the addition of an inorganic base, preferably potassium hydroxide, sodium hydroxide or lithium hydroxide, at a temperature of from 0° C. to 120° C., to give acids of the general formula S-III.

The reaction at stage 9 corresponds to stage 1 in Scheme 1.

Description of the Syntheses ABBREVIATIONS

-   AcOH acetic acid -   aq. aqueous -   d days -   BOP 1-benzotriazolyloxy-tris-(dimethylamino)-phosphonium     hexafluorophosphate -   brine saturated sodium chloride solution DCC     N,N′-dicyclohexylcarbodiimide -   DCM dichloromethane -   DIPEA N,N-diisopropylethylamine -   DMF N,N-dimethylformamide -   DMAP 4-dimethylamino-pyridine -   EDC N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide -   EA ethyl acetate -   ether diethyl ether -   EtOH ethanol -   sat. saturated -   h hour(s) -   HATU O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium     hexafluorophosphate -   HBTU 0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium     hexafluorophosphate -   HOAt 1-hydroxy-7-azabenzotriazole -   sol. solution -   LG leaving group -   m/z mass-to-charge ratio -   MeCN acetonitrile -   MeOH methanol -   min minutes -   MS mass spectrometry -   N/A not available -   NEt₃ triethylamine -   RG retigabine -   RT room temperature 23±7° C. -   CC column chromatography on silica gel -   TBTU 0-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium     tetrafluoroborate -   THF tetrahydrofuran -   vv ratio by volume

All starting materials not described explicitly were either available commercially (suppliers can be found, for example, in the Symyx® Available Chemicals database of MDL, San Ramon, US) or their synthesis has already been described exactly in the specialist literature (experimental procedures can be found, for example, in the Reaxys® database of Elsevier, Amsterdam, NL) or can be prepared by methods known to the person skilled in the art.

Silica gel 60 (0.040-0.063 mm) was used as the stationary phase for column chromatography (CC).

The analytical characterization of all intermediates and exemplary compounds was carried out by means of ¹H-NMR spectroscopy. Investigations by mass spectrometry (MS, m/z indicated for [M+H]⁺) were additionally carried out for all exemplary compounds and chosen intermediates.

Synthesis of the Intermediates Synthesis of intermediate VB006: 2-(4-(4-Fluorophenyl)butyl)-nicotinic acid

4.4 ml (11.0 mmol, 2.5M in hexane) of BuLi solution were added dropwise at −10° C. to a solution of 1.54 ml (11.0 mmol) of diisopropylamine in THF (10 ml). Stirring was then carried out for a further 30 min at −10° C. This solution was added dropwise at −75° C. to a solution of 685 mg (5.0 mmol) of 2-methyl-nicotinic acid in THF (2 ml). Stirring was then carried out for 30 min at −75° C. and for 60 min at 0° C., followed by cooling to −55° C. At that temperature, 1.62 g (7.5 mmol) of 1-(3-bromopropyl)-4-fluorobenzene were added and the reaction solution was stirred for 1 h at −55° C. After warming to RT and stirring for a further 16 h at RT, water (30 ml) and conc. hydrochloric acid (3 ml) were added. Extraction with EA (2×30 ml) was then carried out. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA), yielding 1.28 g (4.7 mmol, 93%) of 2-(4-(4-fluorophenyl)butyl)-nicotinic acid.

Synthesis of intermediate VB007: 2-(4-Phenylbutyl)nicotinic acid

Starting from 2.1 g (15.0 mmol) of 2-methyl-nicotinic acid and 5.5 g (22.5 mmol) of 1-iodo-3-phenyl-propane, 2.9 g (11.3 mmol, 75%) of 2-(4-phenylbutyl)nicotinic acid were obtained according to the process described in precursor VB006.

Synthesis of intermediate VB008: 2-(3-(Phenylsulfonyl)propyl)-nicotinic acid

Starting from 2.1 g (15.0 mmol) of 2-methyl-nicotinic acid and 4.6 g (22.5 mmol) of (2-chloroethyl)-phenylsulfone, 0.7 g (2.4 mmol, 16%) of 2-(3-(phenylsulfonyl)propyl)-nicotinic acid was obtained according to the process described in precursor VB006.

Synthesis of intermediate VC001: (2-Chloro-propan-1-yl)-(phenyl)sulfane/(1-Chloropropan-2-yl)(phenyl)sulfane (5:4 mixture) a) Synthesis of 1-(phenylthio)propan-2-one

13.8 g (100.0 mmol) of K₂CO₃ were added to a solution of 5.1 ml (50.0 mmol) of thiophenol and 4.22 ml (52.5 mmol) of chloroacetone in DMF (30 ml), and the mixture was stirred for 2 h at RT. Concentration in vacuo was then carried out. The residue was purified by means of CC (EA/hex 15:85), yielding 7.7 g (46.3 mmol, 93%) of 1-(phenylthio)propan-2-one.

b) Synthesis of 1-(phenylthio)propan-2-ol

732 mg (19.2 mmol) of NaBH₄ were added in portions, while cooling (ice bath), to a solution of 2.46 g (14.8 mmol) of 1-(phenylthio)propan-2-one in methanol (18 ml). Stirring was then carried out for a further 2 h while cooling (ice bath). The mixture was then quenched with AcOH (17 ml) and then concentrated in vacuo. The residue was taken up in an ether/water mixture and neutralized with NaHCO₃. The phases were separated and the organic phase was dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 15:85), yielding 1.3 g (7.7 mmol, 52%) of 1-(phenylthio)propan-2-ol.

c) Synthesis of a (2-chloro-propan-1-yl)-(phenyl)sulfane/(1-chloropropan-2-yl)(phenyl)sulfane 5:4 mixture

A solution of 1.7 ml (23.0 mmol) of thionyl chloride in toluene (20 ml) was added dropwise, while cooling (ice bath), to a solution of 1.29 g (7.7 mmol) of 1-(phenyl-thio)propan-2-ol and 92 μl (1.2 mmol) of pyridine in toluene (30 ml). The mixture was then heated for 3 h under reflux. After cooling to RT, quenching with an ice/water mixture was carried out. The phases were separated and the aqueous phase was extracted again with toluene. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 1:9), yielding 1.13 g (6.1 mmol, 79%) of a (2-chloro-propan-1-yl)-(phenyl)sulfane/(1-chloropropan-2-yl)(phenyl)sulfane (5:4) mixture. This mixture was used in subsequent reactions without being purified further.

Synthesis of intermediate VC005: 1-(3-Bromo-1,1-difluoropropyl)-4-fluoro-benzene a) Synthesis of 2-(2-(4-fluorophenyl)-1,3-dithiolan-2-yl)ethyl acetate

1.79 g (19.0 mol) of ethane-1,2-dithiol and 680 mg (4.76 mmol) of boron trifluoride etherate were added in succession at 0° C. to a solution of 2.0 g (9.5 mmol) of 3-(4-fluorophenyl)-3-oxopropyl acetate in DCM (40 ml). The mixture was then stirred for 16 h at RT and subsequently neutralized with a 10M aq. NaOH sol. Extraction with DCM (3×100 ml) was then carried out and the combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 24:1) of the residue yielded 1.8 g (6.3 mmol, 66%) of 2-(2-(4-fluoro-phenyl)-1,3-dithiolan-2-yl)ethyl acetate.

b) Synthesis of 3,3-difluoro-3-(4-fluorophenyl)propyl acetate

A 30% HF-pyridine solution (7 ml) and a solution of 500 mg (1.75 mmol) of 2-(2-(4-fluorophenyl)-1,3-dithiolan-2-yl)ethyl acetate in DCM (2 ml) were added in succession at −78° C. to a solution of 2.0 g (7.0 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in DCM (4 ml) in a plastics reaction vessel. The mixture was warmed to 0° C. in the course of 2 h, with stirring, and then neutralized with a sat. aq. NaHCO₃ sol. Extraction with DCM (3×60 ml) was then carried out. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. There were obtained as residue 250 mg (1.08 mmol, 62%) of 3,3-difluoro-3-(4-fluorophenyl)propyl acetate, which was reacted further without additional purification.

c) Synthesis of 3,3-difluoro-3-(4-fluorophenyl)propan-1-ol

A 35% aq. NaOH sol. (6 ml) was added to a solution of 1.9 g (8.2 mmol) of 3,3-difluoro-3-(4-fluorophenyl)propyl acetate in EtOH (25 ml), and the mixture was stirred for 2 h at RT. Concentration in vacuo was then carried out and the residue was taken up in water (80 ml). The solution was extracted with EA (3×80 ml) and the combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 9:1) of the residue yielded 1.1 g (5.8 mmol, 71%) of 3,3-difluoro-3-(4-fluorophenyl)propan-1-ol.

d) Synthesis of 1-(3-bromo-1,1-difluoropropyl)-4-fluorobenzene

3.1 g (9.5 mmol) of tetrabromomethane were added to a solution of 1.0 g (5.3 mmol) of 3,3-difluoro-3-(4-fluorophenyl)propan-1-ol in DCM (20 ml) and cooled to 0° C. At that temperature, 2.48 g (9.5 mmol) of triphenylphosphine were added in portions. Stirring was then carried out for 3 h at RT. The mixture was then diluted with water (50 ml) and extracted with EA (3×60 ml). The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 24:1) of the residue yielded 1.25 g (5.0 mmol, 94%) of 1-(3-bromo-1,1-difluoropropyl)-4-fluorobenzene.

Synthesis of intermediate VC006: 1-(3-Bromobutyl)-3-(trifluoromethyl)benzene a) Synthesis of 4-(3-(trifluoromethyl)phenyl)butan-2-ol

590 mg (15.4 mmol) of LiAlH₄ were added in portions at 0° C. to a solution of 2.2 g (10.3 mmol) of 4-(3-(trifluoromethyl)phenyl)but-3-en-2-one in THF (20 ml), and stirring was then carried out for 1 h at RT. The mixture was then quenched at 0° C. with a sat. aq. Na₂SO₄ sol. and the reaction solution was filtered over kieselguhr. The filtrate was extracted with EA (3×60 ml) and the combined organic phases were washed with water, dried over Na₂SO₄, filtered and concentrated in vacuo. There were obtained as residue 2.0 g (9.2 mmol, 89%) of 4-(3-(trifluoromethyl)phenyl)-butan-2-ol, which was reacted further without additional purification.

b) Synthesis of 1-(3-bromobutyl)-3-(trifluoromethyl)benzene

750 mg (11.0 mmol) of imidazole and 2.88 g (11.0 mmol) of triphenylphosphine were added to a solution of 2.0 g (9.2 mmol) of 4-(3-(trifluoromethyl)phenyl)butan-2-ol in DCM (10 ml). 570 μl (11.0 mmol) of bromine were added dropwise at 0° C., and stirring was carried out for 1 h at RT. The mixture was then concentrated in vacuo. CC (hexane) of the residue yielded 2.0 g (7.1 mmol, 78%) of 1-(3-bromobutyl)-3-(trifluoromethyl)benzene.

Synthesis of Further Intermediates

The synthesis of further intermediates was carried out according to the processes already described. Table 1 shows which compound was prepared by which process. It will be clear to the person skilled in the art which starting materials and reagents were used in each case.

TABLE 1 Preparation analogous Intermediate Chemical name to intermediate VB003 2-(3-(Phenylthio)propyl)nicotinic acid VB006 VB004 2-(3-(3-(Trifluoromethyl)phenyl- VB006 thio)propyl)nicotinic acid VB005 2-(4-(3-Trifluoromethyl- VB006 phenyl)butyl)nicotinic acid VB009 2-(3-(3-(Trifluoromethyl)- VB006 phenylsulfonyl)propyl)nicotinic acid VC002 (2-Chloro-propan-1-yl)(4-fluoro- VC001 phenyl)sulfane/(1-Chloropropan-2- yl)(4-fluoro-phenyl)sulfane (3:2 mixture) VC003 (2-Chloro-propan-1-yl)(3-trifluoro- VC001 methyl-phenyl)sulfane/(1-Chloro- propan-2-yl)(3-trifluoromethyl-phenyl)- sulfane (5:4 mixture) VC004 (2-Chloro-propan-1-yl)(phenyl)sulfane/ see (1-Chloropropan-2-yl)(phenyl)sulfane Example 16 (5:13 mixture)

Synthesis of the Exemplary Compounds Synthesis of exemplary compound 1: 2-(3-Phenyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

227 mg (1.65 mmol) of K₂CO₃ were added to a solution of 375 mg (1.5 mmol) of 2-mercapto-N-(thiophen-2-ylmethyl)nicotinamide in DMF (3.5 ml), and stirring was carried out for 30 min at RT. 369 mg (1.5 mmol) of 1-iodo-3-phenylpropane were then added and stirring was carried out for a further 3 d at RT. The mixture was then concentrated in vacuo and the residue was taken up in an EA/water mixture. The organic phase was separated off and the aqueous phase was extracted again with EA. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 1:1), yielding 382 mg (1.0 mmol, 69%) of 2-(3-phenyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 369.1 [M+H]⁺.

Synthesis of exemplary compound 3: 2-[(3-Oxo-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

227 mg (1.65 mmol) of K₂CO₃ were added to a solution of 375 mg (1.5 mmol) of 2-mercapto-N-(thiophen-2-ylmethyl)nicotinamide in DMF (3.5 ml), and stirring was carried out for 30 min at RT. 252 mg (1.5 mmol) of 3-chloro-1-phenylpropan-1-one were then added and stirring was carried out for a further 2 d at RT. The mixture was then concentrated in vacuo and the residue was taken up in a mixture of EA and a 1N aq. NaHCO₃ sol. The organic phase was separated off and the aqueous phase was extracted again with EA. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 1:1), and subsequent crystallization (EA/hexane) yielded 73 mg (0.2 mmol, 13%) of 2-[(3-oxo-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 383.1 [M+H]⁺.

Synthesis of exemplary compound 13: N-(Thiophen-2-yl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfanyl]-propyl]-pyridine-3-carboxylic acid amide

91 mg (0.6 mmol) of CDI were added to a solution of 240 mg (0.7 mmol) of 2-(3-(3-(trifluoromethyl)phenylthio)propyl)nicotinic acid (VB004) in DCM (7 ml), and stirring was carried out for 30 min at RT. 79 mg (0.7 mmol) of 2-(aminomethyl)thiophene were then added and stirring was carried out for a further 5 d at RT. The mixture was then washed with a 4M aq. NH₄Cl sol. (2×10 ml) and a 1M NaHCO₃ sol. (2×10 ml). The organic phase was dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA), yielding 134 mg (0.3 mmol, 44%). MS: m/z 437.1 [m+H]⁺.

Synthesis of exemplary compound 16: 2-(2-Phenylsulfanyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

1.51 g (11.0 mmol) of K₂CO₃ were added to a solution of 1.25 g (5.0 mmol) of 2-mercapto-N-(thiophen-2-ylmethyl)nicotinamide in DMF (12 ml) and stirring was carried out for 1 h at RT. 930 mg (5.0 mmol) of a (2-chloro-propan-1-yl)(phenyl)-sulfane/(1-chloropropan-2-yl)(phenyl)sulfane 5:4 mixture (VC001) were then added and stirring was carried out for a further 18 h at RT. The mixture was then concentrated in vacuo. The residue was taken up in an EA/water mixture and the phases were separated. The aqueous phase was extracted again with EA and the combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. By means of CC (EA/hex 3:7→1:1) there were recovered 400 mg (2.1 mmol, 43%) of a (2-chloro-propan-1-yl)-(phenyl)sulfane/(1-chloropropan-2-yl)(phenyl)-sulfane 5:13 mixture (VC004) and a mixed fraction containing 2-(2-phenylsulfanyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. From the latter there were isolated by crystallization (EA) 255 mg (0.6 mmol, 13%) of 2-(2-phenylsulfanyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 401.1 [M+H]⁺.

Synthesis of exemplary compound 17: 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

227 mg (1.65 mmol) of K₂CO₃ were added to a solution of 375 mg (1.5 mmol) of 2-mercapto-N-(thiophen-2-ylmethyl)nicotinamide in DMF (6 ml) and stirring was carried out for 1 h at RT. 325 mg (1.5 mmol) of 1-(3-bromopropyl)-4-fluorobenzene were then added and stirring was carried out for a further 16 h at RT. The mixture was then concentrated in vacuo and the residue was taken up in an EA/water mixture. The organic phase was separated off and the aqueous phase was extracted again with EA. The combined organic phases were dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 1:2), yielding 428 mg (1.1 mmol, 74%) of 2-[3-(4-fluorophenyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 3871 [M+H]⁺.

Synthesis of exemplary compound 21: N-(Thiophen-2-yl-methyl)-2-[4-[3-(trifluoromethyl)-phenyl]-butyl]-pyridine-3-carboxylic acid amide

NEt₃ was added to a solution of 323 mg (1.0 mmol) of 2-(4-(3-trifluoromethyl-phenyl)butyl)nicotinic acid (VB005), 113 mg (1.0 mmol) of 2-(aminomethyl)-thiophene and 381 mg (1.0 mmol) of HATU in THF (8 ml) and stirring was carried out for 4 d at RT. The mixture was then concentrated in vacuo. The residue was taken up in EA and washed with a 1M aq. NH₄Cl sol. and a 1M aq. NaHCO₃ sol. The organic phase was dried over MgSO₄, filtered and concentrated in vacuo. The residue was purified by means of CC (EA/hex 3:1), yielding 221 mg (0.5 mmol, 53%). MS: m/z 419.1 [M+H]⁺.

Synthesis of exemplary compound 42: N-(3,3-Dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide

a) Synthesis of 2-(3-(4-fluorophenyl)propylthio)nicotinic acid

4.9 g (35.8 mmol) of K₂CO₃ were added to a solution of 2.5 g (16.3 mmol) of 2-mercapto-nicotinic acid in DMF (40 ml), and the mixture was stirred for 30 min at RT. 3.5 g (16.3 mmol) of 1-(3-bromopropyl)-4-fluorobenzene were then added and stirring was carried out for a further 72 h at RT. The mixture was then diluted with water and EA and adjusted to pH 5-6 with 5M acetic acid. The organic phase was separated off, washed with water, dried over MgSO₄, filtered and concentrated in vacuo. CC (EA/hexane 1:2→5:1) of the residue yielded 2.2 g (7.6 mmol, 47%) of 2-(3-(4-fluoro-phenyl)propylthio)nicotinic acid.

b) Synthesis of N-(3,3-dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide

274 mg (0.72 mmol) of HATU and 100 ml (0.72 mmol) of NEt₃ were added to a solution of 200 mg (0.69 mmol) of 2-(3-(4-fluorophenyl)propylthio)nicotinic acid and 92 ml (0.69 mmol) of 3,3-dimethyl-butylamine in THF (11 ml), and the mixture was stirred for 16 h at RT. Dilution with EA was then carried out. The organic phase was separated off, washed with a 1M aq. Na₂CO₃ sol. and a 4M aq. NH₄Cl sol., dried over MgSO₄, filtered and concentrated in vacuo. CC (hexane/EA 2:1) of the residue yielded 173 mg (0.46 mmol, 67%) of N-(3,3-dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 375.2 [M+H]⁺.

Synthesis of exemplary compound 50: N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-3-hydroxy-propyl]sulfanyl]-pyridine-3-carboxylic acid amide

A solution of 400 mg (0.97 mmol) of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-3-oxo-propyl]sulfanyl]-pyridine-3-carboxylic acid amide (exemplary compound 43) in MeOH (10 ml) was cooled to 0° C., and 18 mg (0.49 mmol) of NaBH₄ were added in portions. Stirring was then carried out for 2 h at 0° C. and for 1 h at RT. The reaction solution was then poured onto ice-water and extraction with DCM was carried out. The organic phase was dried over MgSO₄, filtered and concentrated in vacuo. CC (hexane/EA 2:1→1:1) of the residue yielded 180 mg (0.43 mmol, 45%) of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-3-hydroxy-propyl]sulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 415.2 [m+H]⁺.

Synthesis of exemplary compound 51: N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide

a) Synthesis of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide

5.0 g (40.0 mmol) of bicyclo[2.2.1]heptan-2-ylmethanamine, 16.0 g (42.0 mmol) of HATU and 5.8 ml (42.0 mmol) of NEt₃ were added in succession to a solution of 6.2 g (40.0 mmol) of 2-mercapto-nicotinic acid in THF (320 ml), and the mixture was stirred for 4 d at RT. Dilution with EA was then carried out. The organic phase was separated off, washed with a 1M aq. Na₂CO₃ sol. and a 4M aq. NH₄Cl sol., dried over MgSO₄, filtered and concentrated in vacuo. CC (hexane/EA 7:3→1:1→3:7) was carried out with the residue. The resulting prepurified product was dissolved in 1N aq. NaOH (100 ml) and the solution was washed with ether. The aqueous phase was adjusted to pH ˜2 with 2M hydrochloric acid. The resulting precipitate was filtered off and then washed with pentane and dried in vacuo. 5.3 g (20.2 mmol, 50%) of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide were obtained.

b) Synthesis of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propyl-sulfanyl]-pyridine-3-carboxylic acid amide

178 mg (1.29 mmol) of K₂CO₃ were added to a solution of 308 mg (1.18 mmol) of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide in DMF (5 ml), and the mixture was stirred for 60 min at RT. 255 mg (1.18 mmol) of 1-(3-bromopropyl)-4-fluorobenzene were then added and the mixture was stirred for a further 16 h at RT. Dilution with water and extraction with EA were then carried out. The organic phase was washed with water, dried over MgSO₄, filtered and concentrated in vacuo. CC (hexane/EA 2:1) of the residue yielded 333 mg (0.83 mmol, 71%) of N-(5-bicyclo-[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propyl-sulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 399.2 [M+H]⁺.

Synthesis of exemplary compound 58: N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-hydroxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide

A solution of 483 mg (1.18 mmol) of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-methoxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide (exemplary compound 56) in DCM (50 ml) was cooled to −60° C.; 11.8 ml (11.8 mmol, 1M in DCM) of boron tribromide were added at that temperature and stirring was carried out for 90 min at −60° C. After warming to RT, the mixture was quenched with a 1M aq.

NaHCO₃ sol. and the phases were separated. The aqueous phase was extracted with EA and the organic phases were combined, washed with water, dried over MgSO₄, filtered and concentrated in vacuo. Crystallization (hexane/EA 2:1) of the residue yielded 393 mg (0.99 mmol, 84%) of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-hydroxy-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 397.2 [M+H]⁺.

Synthesis of exemplary compound 112: 2-(3-Phenyl-propylsulfanyl)-6-pyrrolidin-1-yl-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

153 mg of K₂CO₃ and 71 mg (1.0 mmol) of pyrrolidine were added to a solution of 387 mg (1.0 mmol) of 6-fluoro-2-(3-phenylpropylthio)-N-(thiophen-2-ylmethyl)-pyridine-3-carboxylic acid amide (exemplary compound 225) in DMF (10 ml), and the mixture was stirred for 2 h at RT. Dilution with water and extraction with EA were then carried out. The organic phase was washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 7:3) of the residue yielded 308 mg (0.7 mmol, 71%) of 2-(3-phenyl-propylsulfanyl)-6-pyrrolidin-1-yl-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 438.2 [M+H]⁺.

Synthesis of exemplary compound 115: N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide

a) Synthesis of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide

4.82 g (15.0 mmol) of TBTU and 3.54 g (35 mmol) of N-methyl-morpholine were added to a solution of 1.55 g (10.0 mmol) of 2-mercapto-nicotinic acid in DMF (30 ml), and the mixture was stirred for 30 min at RT. 1.25 g (10.0 mmol) of bicyclo-[2.2.1]heptan-2-ylmethanamine were then added, and stirring was carried out for 16 h at RT. The mixture was then diluted with EA and washed with sat. aq. NH₄Cl sol., a 1N aq. NaHCO₃ sol. and brine. The organic phase was dried over Na₂SO₄, filtered and concentrated in vacuo. CC (DCM/MeOH 99:1) of the residue yielded 308 mg 1.39 g (5.3 mmol, 53%) of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide.

b) Synthesis of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid

553 mg (4 mmol) of K₂CO₃ and 268 mg (1.0 mmol) of 3,3-difluoro-3-(4-fluorophenyl)-propyl methanesulfonate were added in succession to a solution of 262 mg (1.0 mmol) of N-(bicyclo[2.2.1]heptan-2-ylmethyl)-2-mercapto-nicotinamide in DMF (3 ml), and the mixture was heated for 3 h at 60° C. Dilution with water and extraction with EA were then carried out. The organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 7:3) of the residue yielded 229 mg (0.5 mmol, 53%) of N-(5-bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluoro-phenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 435.2 [M+H]⁺.

Synthesis of exemplary compound 126: 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-hydroxy-3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide

70 mg (1.8 mmol) of NaBH₄ were added in portions at 0° C. to a solution of 350 mg (0.9 mmol) of N-(3,3-dimethyl-2-oxo-butyl)-2-[3-(4-fluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide (exemplary compound 125) in EtOH (7 ml). Stirring was then carried out for 2 h at RT. The mixture was then cooled to 0° C., quenched with a sat. aq. NH₄Cl sol. (20 ml) and concentrated in vacuo. The residue was taken up in EA and the solution was washed with a 1M aq. NaHCO₃ sol., water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 3:2) of the residue yielded 320 mg (0.82 mmol, 91%) of 2-[3-(4-fluorophenyl)-propylsulfanyl]-N-(2-hydroxy-3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide. MS: m/z 391.2 [M+H]⁺.

Synthesis of exemplary compound 131: 3-[[[2-[3-(4-Fluorophenyl)-propylsulfanyl]-pyridine-3-carbonyl]amino]-methyl]-benzoic acid

A solution of 120 mg (2.92 mmol) of lithium hydroxide monohydrate in water (4 ml) was added to a solution of 320 mg (0.73 mmol) of 3-[[[2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carbonyl]amino]-methyl]-benzoic acid methyl ester (exemplary compound 129) in a MeOH/THF mixture (2:1 vv, 9 ml), and the mixture was stirred for 16 h at RT. Concentration in vacuo was then carried out. The residue was taken up in water and washed with EA. The aqueous phase was then adjusted to pH ˜2 with 2M hydrochloric acid at 0° C. The resulting precipitate was filtered off, taken up in toluene and concentrated in vacuo. The residue was washed with an ether/pentane mixture (1:4 vv), yielding 170 mg (0.4 mmol, 55%) of 3-[[[2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carbonyl]amino]-methyl]-benzoic acid. MS: m/z 425.1 [m+H]⁺.

Synthesis of exemplary compound 143: 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(pyridin-2-yl-methyl)-pyridine-3-carboxylic acid amide

a) Synthesis of 2-(3-(4-fluorophenyl)propylthio)nicotinic acid

2-(3-(4-Fluorophenyl)propylthio)nicotinic acid was prepared according to the process described in exemplary compound 169 section a).

b) Synthesis of 2-[3-(4-fluorophenyl)-propylsulfanyl]-N-(pyridin-2-yl-methyl)-pyridine-3-carboxylic acid amide

520 mg (2.74 mmol) of EDC hydrochloride, 250 mg (1.64 mmol) of HOBT, 0.9 ml (5.48 mmol) of DIPEA and 180 mg (1.64 mmol) of pyridin-2-yl-methanamine were added in succession to a solution of 400 mg (1.37 mmol) of 2-(3-(4-fluorophenyl)-propylthio)nicotinic acid in DCM (6 ml), and the mixture was stirred for 4 h at RT. Dilution with water (40 ml) and extraction with DCM (3×50 ml) were then carried out. The combined organic phases were washed with a sat. NH₄Cl sol. and water, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 22:3) of the residue yielded 240 mg (0.63 mmol, 46%) of 2-[3-(4-fluorophenyl)-propylsulfanyl]-N-(pyridin-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 382.1 [M+H]⁺.

Synthesis of exemplary compound 147: 2-[3-(4-Fluorophenyl)-propylsulfanyl]-4-methyl-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

a) Synthesis of 2-(3-(4-fluorophenyl)propylthio)-4-methylnicotinenitrile

4.14 g (30 mmol) of K₂CO₃ and 5.2 g (30 mmol) of 1-(3-chloropropyl)-4-fluoro-benzene were added to a solution of 3.0 g (20 mmol) of 2-mercapto-4-methyl-nicotinenitrile in acetone (60 ml), and the mixture was then heated for 16 h at 60° C. Filtration over kieselguhr was then carried out and the filtrate was diluted with water (50 ml). Washing with EA (200 ml) was then carried out. The aqueous phase was acidified with 6M hydrochloric acid (50 ml) and then extracted with EA (3×100 ml). The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 9:1) of the residue yielded 3.5 g (12 mmol, 61%) of 2-(3-(4-fluorophenyl)propylthio)-4-methylnicotine-nitrile.

b) Synthesis of 2-(3-(4-fluorophenyl)propylthio)-4-methylnicotinic acid

50% sulfuric acid (8 ml) was added to 500 mg (1.74 mmol) of 2-(3-(4-fluorophenyl)-propylthio)-4-methylnicotinenitrile, and the reaction solution was heated for 6 d at 140° C. The mixture was then poured onto ice-water and extracted with EA (3×100 ml). The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. There were obtained as residue 400 mg (1.31 mmol, 75%) of 2-(3-(4-fluorophenyl)propylthio)-4-methylnicotinic acid, which was reacted further without additional purification.

c) Synthesis of 2-[3-(4-fluorophenyl)-propylsulfanyl]-4-methyl-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide

From 200 mg (0.66 mmol) of 2-(3-(4-fluorophenyl)propylthio)-4-methylnicotinic acid and 80 μl (0.79 mmol) of thiophen-2-yl-methanamine there were prepared, according to the process described for exemplary compound 169 section b), 120 mg (0.30 mmol, 45%) of 2-[3-(4-fluorophenyl)-propylsulfanyl]-4-methyl-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide. MS: m/z 401.1 [M+H]⁺.

Synthesis of exemplary compound 167: N-(3,3-Dimethyl-butyl)-2-[(2-oxo-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic acid amide

a) Synthesis of N-(3,3-dimethylbutyl)-2-mercapto-nicotinamide

5.84 ml (33.8 mmol) of DIPEA and 4.66 g (14.5 mmol) of TBTU were added at 0° C. to a solution of 1.50 g (9.7 mmol) of 2-mercapto-nicotinic acid in DMF (30 ml). After stirring for 30 min at 0° C., 1.6 ml (11.6 mmol) of 3,3-dimethylbutan-1-amine were added and then the mixture was stirred for 16 h at RT. Dilution with water (100 ml) and extraction with EA (2×100 ml) were then carried out. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/acetone 1:1) of the residue yielded 1.4 g (5.9 mmol, 61%) of N-(3,3-dimethylbutyl)-2-mercapto-nicotinamide.

b) Synthesis of N-(3,3-dimethyl-butyl)-2-[(2-oxo-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic acid

840 mg (6.1 mmol) of K₂CO₃ and 340 mg (2.0 mmol) of 1-chloro-3-phenylpropan-2-one were added to a solution of 450 mg (2.0 mmol) of N-(3,3-dimethylbutyl)-2-mercapto-nicotinamide in acetone (10 ml), and the mixture was then heated for 1 h at 50° C. Dilution with water (20 ml) and extraction with EA (2×30 ml) were then carried out. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 4:1) of the residue yielded 420 mg (1.1 mmol, 56%) of N-(3,3-dimethyl-butyl)-2-[(2-oxo-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic acid amide. MS: m/z 371.2 [M+H]⁺.

Synthesis of exemplary compound 169: 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide

a) Synthesis of 2-(3,3-difluoro-3-(4-fluorophenyl)propylthio)nicotinic acid

1.02 g (4.0 mmol) of 1-(3-bromo-1,1-difluoropropyl)-4-fluorobenzene (precursor VC005) and 1.67 g (12.0 mmol) of K₂CO₃ were added to a solution of 620 mg (4.0 mmol) of 2-mercapto-nicotinic acid in DMF (10 ml), and the mixture was heated for 2 h at 90° C. Dilution with water (20 ml) was then carried out, and the pH was adjusted to −2 with 6M hydrochloric acid. Extraction with EA (3×40 ml) was then carried out. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 1:4) of the residue yielded 400 mg (1.2 mmol, 31%) of 2-(3,3-difluoro-3-(4-fluorophenyl)propylthio)-nicotinic acid.

b) Synthesis of 2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide

320 μl (1.83 mmol) of DIPEA and 350 mg (0.91 mmol) of HATU were added at 0° C. to a solution of 150 mg (0.46 mmol) of 2-(3,3-difluoro-3-(4-fluorophenyl)propylthio)-nicotinic acid in DCM (10 ml). After stirring for 30 min at 0° C., 63 μl (0.55 mmol) of 3-methylbutan-1-amine were added and then the mixture was stirred for 16 h at RT. Dilution with water (20 ml) and extraction with DCM (2×20 ml) were then carried out. The combined organic phases were washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (EA/hexane 7:3) of the residue yielded 100 mg (0.25 mmol, 55%) of 2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]-sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide. MS: m/z 397.1 [m+H]⁺.

Synthesis of exemplary compound 225: 6-Fluoro-2-(3-phenylpropylthio)-N-(thiophen-2-ylmethyl)pyridine-3-carboxylic acid amide

a) Synthesis of 2,6-difluoro-N-(thiophen-2-ylmethyl)nicotinamide

795 mg (5.0 mmol) of 2,6-difluoro-nicotinic acid were dissolved in thionyl chloride (15 ml) and the solution was heated for 2 h at 80° C. Concentration in vacuo was then carried out and the residue was taken up in dioxane (15 ml). 566 mg (5.0 mmol) of thiophen-2-yl-methanamine were then added and the mixture was stirred for 1 h at RT. Concentration in vacuo was then carried out and the residue was taken up in EA, washed with water, a sat. aq. Na₂CO₃ sol., water again and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 7:3) of the residue yielded 605 mg (2.4 mmol, 48%) of 2,6-difluoro-N-(thiophen-2-ylmethyl)nicotinamide.

b) Synthesis of 6-fluoro-2-(3-phenylpropylthio)-N-(thiophen-2-ylmethyl)pyridine-3-carboxylic acid amide

919 mg (6.0 mmol) of K₂CO₃ and 305 mg (2.0 mmol) of 3-phenylpropane-1-thiol were added to a solution of 509 mg (2.0 mmol) of 2,6-difluoro-N-(thiophen-2-ylmethyl)-nicotinamide in DMF (10 ml), and the mixture was stirred for 1 h at RT. Dilution with water and extraction with EA were then carried out. The organic phase was washed with water and brine, dried over Na₂SO₄, filtered and concentrated in vacuo. CC (hexane/EA 4:1) of the residue yielded 336 mg (0.9 mmol, 43%) of 6-fluoro-2-(3-phenylpropylthio)-N-(thiophen-2-ylmethyl)pyridine-3-carboxylic acid amide. MS: m/z 387.1 [M+H]⁺.

Synthesis of Further Exemplary Compounds

The synthesis of further exemplary compounds was carried out according to the processes already described. Table 2 shows which compound was prepared by which process. It will be clear to the person skilled in the art which starting materials and reagents were used in each case.

TABLE 2 Synthesis Exem- analogous MS plary to m/z com- exemplary [M + pound Chemical name compound H]⁺ 2 2-(3-Cyclohexyl-propylsulfanyl)-N- 17 375.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 4 N-(Thiophen-2-yl-methyl)-2-[2-[3- 17 439.1 (trifluoromethyl)-phenoxy]-ethylsulfanyl]- pyridine-3-carboxylic acid amide 5 2-(4-Methyl-pentylsulfanyl)-N-(thiophen- 17 335.1 2-yl-methyl)-pyridine-3-carboxylic acid amide 7 2-(4-Phenyl-butyl)-N-(thiophen-2-yl- 13 351.1 methyl)-pyridine-3-carboxylic acid amide 8 2-[3-(Benzenesulfonyl)-propyl]-N- 13 401.2 (cyclohexyl-methyl)-pyridine-3-carboxylic acid amide 9 N-(Cyclohexyl-methyl)-2-(4-phenyl- 13 351.2 butyl)-pyridine-3-carboxylic acid amide 10 2-[3-(Benzenesulfonyl)-propyl]-N- 13 401.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 12 N-(Thiophen-2-yl-methyl)-2-[3-[[3- 13 469.1 (trifluoromethyl)phenyl]sulfonyl]-propyl]- pyridine-3-carboxylic acid amide 18 N-(Thiophen-2-yl-methyl)-2-[3-[3- 17 437.1 (trifluoromethyl)phenyl]-propylsulfanyl]- pyridine-3-carboxylic acid amide 19 2-[2-[(4-Fluorophenyl)sulfanyl]- 16 (aus 419.1 propylsulfanyl]-N-(thiophen-2-yl-methyl)- VC002) pyridine-3-carboxylic acid amide 20 N-(Thiophen-2-yl-methyl)-2-[2-[[3- 16 (aus 469.1 (trifluoromethyl)phenyl]sulfanyl]- VC003) propylsulfanyl]-pyridine-3-carboxylic acid amide 22 2-[4-(4-Fluorophenyl)-butyl]-N-(thiophen- 21 369.1 2-yl-methyl)-pyridine-3-carboxylic acid amide 23 2-(3-Phenylsulfanyl-propyl)-N-(thiophen- 21 369.1 2-yl-methyl)-pyridine-3-carboxylic acid amide 24 2-[(1-Methyl-2-phenylsulfanyl- 16 (aus 401.1 ethyl)sulfanyl]-N-(thiophen-2-yl-methyl)- VC004) pyridine-3-carboxylic acid amide 25 N-(Cycloheptyl-methyl)-2-[4-[3- 17 433.2 (trifluoromethyl)phenyl]-butyl]-pyridine-3- carboxylic acid amide 26 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[4- 17 431.2 [3-(trifluoromethyl)phenyl]-butyl]- pyridine-3-carboxylic acid amide 27 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 449.2 [3-(trifluoromethyl)phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 28 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(4- 51 347.2 methyl-pentylsulfanyl)-pyridine-3- carboxylic acid amide 29 N-(Cycloheptyl-methyl)-2-[3-[(4- 21 401.2 fluorophenyl)sulfanyl]-propyl]-pyridine-3- carboxylic acid amide 30 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 21 399.2 [(4-fluorophenyl)sulfanyl]-propyl]- pyridine-3-carboxylic acid amide 31 N-(Cycloheptyl-methyl)-2-[3-[[3- 21 483.2 (trifluoromethyl)phenyl]sulfonyl]-propyl]- pyridine-3-carboxylic acid amide 32 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 21 481.2 [[3-(trifluoromethyl)phenyl]sulfonyl]- propyl]-pyridine-3-carboxylic acid amide 33 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3- 51 381.2 phenyl-propylsulfanyl)-pyridine-3- carboxylic acid amide 34 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 449.2 [4-(trifluoromethyl)-phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 35 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 415.2 (4-chlorophenyl)-propylsulfanyl]-pyridine- 3-carboxylic acid amide 36 N-[(3,5-Difluoro-phenyl)-methyl]-2-[3-(4- 42 417.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 37 N-[(5-Chloro-thiophen-2-yl)-methyl]-2-[3- 42 421.1 (4-fluorophenyl)-propylsulfanyl]-pyridine- 3-carboxylic acid amide 38 N-[(2,2-Dimethyl-cyclopropyl)-methyl]-2- 42 373.2 [3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 39 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 399.2 (3-fluorophenyl)-propylsulfanyl]-pyridine- 3-carboxylic acid amide 40 N-(Cyclohexyl-methyl)-2-[3-(4- 42 387.2 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 41 N-(Cycloheptyl-methyl)-2-[3-(4- 42 401.2 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 43 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 413.2 [[3-(4-fluorophenyl)-3-oxo- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 44 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 395.2 [(3-oxo-3-phenyl-propyl)sulfanyl]- pyridine-3-carboxylic acid amide 45 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 347.2 (hexylsulfanyl)-pyridine-3-carboxylic acid amide 46 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(2- 51 383.2 phenoxy-ethylsulfanyl)-pyridine-3- carboxylic acid amide 47 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2- 51 451.2 [3-(trifluoromethyl)-phenoxy]- ethylsulfanyl]-pyridine-3-carboxylic acid amide 48 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 51 387.1 (3,3,3-trifluoro-propyl)-pyridine-3- carboxylic acid amide 49 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2- 51 401.2 (4-fluoro-phenoxy)-ethylsulfanyl]- pyridine-3-carboxylic acid amide 52 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3- 51 431.2 naphthalen-1-yl-propylsulfanyl)-pyridine- 3-carboxylic acid amide 53 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 467.2 [3-fluoro-4-(trifluoromethyl)-phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 54 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 467.2 [4-fluoro-3-(trifluoromethyl)-phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 55 N-(Cyclooctyl-methyl)-2-[3-(4- 42 415.2 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 56 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 411.2 (4-methoxyphenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 57 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 411.1 [(4-methoxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 59 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 449.1 [[3-(trifluoromethyl)phenyl]-methyl]- pyridine-3-carboxylic acid amide 60 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 417.2 (3,4-difluoro-phenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 61 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 417.2 (3,5-difluoro-phenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 62 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 417.2 (2,4-difluoro-phenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 63 N-[(2-Fluorophenyl)-methyl]-2-[3-(4- 42 399.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 64 N-[(3-Fluorophenyl)-methyl]-2-[3-(4- 42 399.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 65 N-[(4-Fluorophenyl)-methyl]-2-[3-(4- 42 399.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 66 N-Benzyl-2-[3-(4-fluorophenyl)- 42 381.1 propylsulfanyl]-pyridine-3-carboxylic acid amide 67 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 395.2 [(1-methyl-3-phenyl-propyl)sulfanyl]- pyridine-3-carboxylic acid amide 68 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 435.2 (3,4,5-trifluoro-phenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 69 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 467.2 [3-fluoro-5-(trifluoromethyl)-phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 70 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 411.2 (3-methoxyphenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 71 N-[(3,4-Difluoro-phenyl)-methyl]-2-[3-(4- 42 417.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 72 N-(2,3-Dihydro-benzofuran-5-yl-methyl)- 42 423.1 2-[3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 73 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 58 397.2 (3-hydroxyphenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 74 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 413.2 [[3-(4-fluorophenyl)-1-methyl- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 75 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2- 51 413.2 [[3-(4-fluorophenyl)-2-methyl- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 76 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 411.1 [(2-methoxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 77 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 411.1 [(3-methoxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 78 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 395.2 phenethyl-pyridine-3-carboxylic acid amide 79 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 465.1 [[4-(trifluoromethyloxy)-phenyl]-methyl]- pyridine-3-carboxylic acid amide 80 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 449.1 [[4-(trifluoromethyl)-phenyl]-methyl]- pyridine-3-carboxylic acid amide 81 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 396.1 (2-pyridine-3-yl-ethyl)-pyridine-3- carboxylic acid amide 82 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 396.1 (2-pyridine-2-yl-ethyl)-pyridine-3- carboxylic acid amide 83 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 58 397.1 [(2-hydroxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 84 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 58 397.1 [(3-hydroxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 85 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 409.2 [2-(m-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 86 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 409.2 [2-(o-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 87 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 465.1 [[3-(trifluoromethyloxy)-phenyl]-methyl]- pyridine-3-carboxylic acid amide 88 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 397.1 [(4-hydroxyphenyl)-methyl]-pyridine-3- carboxylic acid amide 89 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 396.1 (2-pyridine-4-yl-ethyl)-pyridine-3- carboxylic acid amide 90 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 409.2 [2-(p-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 91 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 413.2 (4-fluorophenyl)-butylsulfanyl]-pyridine-3- carboxylic acid amide 92 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 51 435.2 (2,4,5-trifluoro-phenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 93 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 410.2 (3-pyridine-2-yl-propyl)-pyridine-3- carboxylic acid amide 94 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 410.2 (3-pyridine-3-yl-propyl)-pyridine-3- carboxylic acid amide 95 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 410.2 (3-pyridine-4-yl-propyl)-pyridine-3- carboxylic acid amide 96 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 42 333.1 propyl-pyridine-3-carboxylic acid amide 97 N-Butyl-2-[3-(4-fluorophenyl)- 42 347.2 propylsulfanyl]-pyridine-3-carboxylic acid amide 98 2-(3-Pyridin-3-yl-propylsulfanyl)-N- 167 370.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 99 2-[3-(p-Tolyl)-propylsulfanyl]-N- 167 383.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 100 2-(4-Phenyl-butylsulfanyl)-N-(thiophen-2- 51 383.1 yl-methyl)-pyridine-3-carboxylic acid amide 101 2-(3-Pyridin-4-yl-propylsulfanyl)-N- 51 370.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 102 2-(3-Naphthalen-2-yl-propylsulfanyl)-N- 51 419.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 103 2-[3-(m-Tolyl)-propylsulfanyl]-N- 167 383.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 104 N-(Thiophen-2-yl-methyl)-2-(3-thiophen- 167 375.1 2-yl-propylsulfanyl)-pyridine-3-carboxylic acid amide 105 2-[(1-Methyl-3-phenyl-propyl)sulfanyl]-N- 51 383.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 106 N-(Thiophen-2-yl-methyl)-2-(3-thiophen- 167 375.1 3-yl-propylsulfanyl)-pyridine-3-carboxylic acid amide 107 2-[[1-Methyl-3-[3-(trifluoromethyl)phenyl]- 167 451.1 propyl]sulfanyl]-N-(thiophen-2-yl-methyl)- pyridine-3-carboxylic acid amide 108 2-[(2-Benzyl-cyclohexyl)sulfanyl]-N- 115 423.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 109 2-[3-[3-Methyl-5-(trifluoromethyl)- 115 451.1 phenyl]-propylsulfanyl]-N-(thiophen-2-yl- methyl)-pyridine-3-carboxylic acid amide 110 2-[4-(3,4-Difluoro-phenyl)-butylsulfanyl]- 115 419.1 N-(thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 111 2-(3-Pyridin-2-yl-propylsulfanyl)-N- 225 370.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 113 2-[3-[4-Methyl-3-(trifluoromethyl)- 115 451.1 phenyl]-propylsulfanyl]-N-(thiophen-2-yl- methyl)-pyridine-3-carboxylic acid amide 114 2-[(3-Phenyl-cyclohexyl)sulfanyl]-N- 115 409.1 (thiophen-2-yl-methyl)-pyridine-3- carboxylic acid amide 116 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 115 411.2 propyl]sulfanyl]-N-(3,3-dimethyl-butyl)- pyridine-3-carboxylic acid amide 117 N-(Cycloheptyl-methyl)-2-[[3,3-difluoro-3- 115 437.2 (4-fluorophenyl)-propyl]sulfanyl]-pyridine- 3-carboxylic acid amide 118 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 115 423.1 propyl]sulfanyl]-N-(thiophen-2-yl-methyl)- pyridine-3-carboxylic acid amide 119 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 435.2 (1,2,3,4-tetrahydro-naphthalen-2-yl- methyl)-pyridine-3-carboxylic acid amide 120 N-(2,3-Dihydro-1H-inden-2-yl-methyl)-2- 169 421.2 [3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 121 N-(1,3-Benzodioxol-5-yl-methyl)-2-[3-(4- 169 425.1 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 122 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 457.2 [(3-phenyl-phenyl)-methyl]-pyridine-3- carboxylic acid amide 123 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 401.2 [(3-methyl-cyclohexyl)-methyl]-pyridine- 3-carboxylic acid amide 124 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 115 435.1 propyl]sulfanyl]-N-[(4-fluorophenyl)- methyl]-pyridine-3-carboxylic acid amide 125 N-(3,3-Dimethyl-2-oxo-butyl)-2-[3-(4- 169 389.2 fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 127 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 382.1 (pyridin-3-yl-methyl)-pyridine-3- carboxylic acid amide 128 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 382.1 (pyridin-4-yl-methyl)-pyridine-3- carboxylic acid amide 129 3-[[[2-[3-(4-Fluorophenyl)-propylsulfanyl]- 169 439.1 pyridine-3-carbonyl]amino]-methyl]- benzoic acid methyl ester 130 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 439.2 [3-(2-methoxyphenyl)-propyl]-pyridine-3- carboxylic acid amide 132 N-[(4-Fluorophenyl)-methyl]-2-[[1-methyl- 51 463.1 3-[3-(trifluoromethyl)phenyl]- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 133 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 361.2 (3-methyl-butyl)-pyridine-3-carboxylic acid amide 134 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 389.2 (tetrahydro-pyran-2-yl-methyl)-pyridine- 3-carboxylic acid amide 135 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 399.2 [3-(1H-pyrazol-1-yl)-propyl]-pyridine-3- carboxylic acid amide 136 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 431.2 (naphthalen-2-yl-methyl)-pyridine-3- carboxylic acid amide 137 N-(2,3-Dihydro-[1,4]benzodioxin-6-yl- 169 439.1 methyl)-2-[3-(4-fluorophenyl)- propylsulfanyl]-pyridine-3-carboxylic acid amide 138 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 466.2 [(3-morpholin-4-yl-phenyl)-methyl]- pyridine-3-carboxylic acid amide 139 N-(2,3-Dihydro-benzofuran-6-yl-methyl)- 169 423.1 2-[3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 140 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 447.2 [[3-(1H-pyrazol-1-yl)-phenyl]-methyl]- pyridine-3-carboxylic acid amide 141 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 400.2 [3-(1H-[1,2,3]triazol-1-yl)-propyl]- pyridine-3-carboxylic acid amide 142 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 169 399.2 (4-fluorophenyl)-propylsulfanyl]-pyridine- 3-carboxylic acid amide 144 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 388.1 (thiazol-2-yl-methyl)-pyridine-3- carboxylic acid amide 145 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 388.1 (thiazol-5-yl-methyl)-pyridine-3- carboxylic acid amide 146 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 372.1 (oxazol-2-yl-methyl)-pyridine-3- carboxylic acid amide 148 N-(3,3-Dimethyl-butyl)-2-[3-(4- 147 389.2 fluorophenyl)-propylsulfanyl]-4-methyl- pyridine-3-carboxylic acid amide 149 N-(3,3-Dimethyl-butyl)-2-[[1-methyl-3-[3- 115 439.2 (trifluoromethyl)phenyl]-propyl]sulfanyl]- pyridine-3-carboxylic acid amide 150 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 432.1 (quinolin-7-yl-methyl)-pyridine-3- carboxylic acid amide 151 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 458.2 [(3-pyridin-2-yl-phenyl)-methyl]-pyridine- 3-carboxylic acid amide 152 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 458.2 [(3-pyridin-3-yl-phenyl)-methyl]-pyridine- 3-carboxylic acid amide 153 N-(3,3-Dimethyl-butyl)-2-[[(1R)-1-methyl- 115 371.2 3-phenyl-propyl]sulfanyl]-pyridine-3- carboxylic acid amide 154 N-(3,3-Dimethyl-butyl)-2-[[(1S)-1-methyl- 115 371.2 3-phenyl-propyl]sulfanyl]-pyridine-3- carboxylic acid amide 155 2-[(2-Benzyl-cyclopentyl)sulfanyl]-N-(3,3- 115 397.2 dimethyl-butyl)-pyridine-3-carboxylic acid amide 156 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 169 449.2 [3-(trifluoromethyl)phenyl]- propylsulfanyl]-pyridine-3-carboxylic acid amide 157 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 400.2 [3-(1H-[1,2,4]triazol-1-yl)-propyl]- pyridine-3-carboxylic acid amide 158 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 373.1 ([1,3,4]oxadiazol-2-yl-methyl)-pyridine-3- carboxylic acid amide 159 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 143 458.2 [(3-pyridin-4-yl-phenyl)-methyl]-pyridine- 3-carboxylic acid amide 160 N-[[4-(Cyclopropyl-methyl)-3,4-dihydro- 169 492.2 2H-[1,4]benzoxazin-6-yl]-methyl]-2-[3-(4- fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 161 N-[(4-Ethyl-3,4-dihydro-2H- 169 466.2 [1,4]benzoxazin-6-yl)-methyl]-2-[3-(4- fluorophenyl)-propylsulfanyl]-pyridine-3- carboxylic acid amide 162 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 452.2 [(4-methyl-3,4-dihydro-2H- [1,4]benzoxazin-6-yl)-methyl]-pyridine-3- carboxylic acid amide 163 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 437.2 (3-methyl-3-phenyl-butyl)-pyridine-3- carboxylic acid amide 164 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2- 115 435.2 [[3,3-difluoro-3-(4-fluorophenyl)- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 165 2-[[3,3-Difluoro-3-[3- 115 485.1 (trifluoromethyl)phenyl]-propyl]sulfanyl]- N-[(4-fluorophenyl)-methyl]-pyridine-3- carboxylic acid amide 166 2-[[3,3-Difluoro-3-[3- 169 461.2 (trifluoromethyl)phenyl]-propyl]sulfanyl]- N-(3,3-dimethyl-butyl)-pyridine-3- carboxylic acid amide 168 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 435.1 propyl]sulfanyl]-N-[(3-fluorophenyl)- methyl]-pyridine-3-carboxylic acid amide 170 N-Butyl-2-[[3,3-difluoro-3-(4- 169 383.1 fluorophenyl)-propyl]sulfanyl]-pyridine-3- carboxylic acid amide 171 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 385.1 propyl]sulfanyl]-N-(2-methoxy-ethyl)- pyridine-3-carboxylic acid amide 172 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 349.1 (2-methoxy-ethyl)-pyridine-3-carboxylic acid amide 173 N-[(4-Fluoro-2-hydroxy-phenyl)-methyl]- 58 415.1 2-[3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide 174 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 371.1 (furan-2-yl-methyl)-pyridine-3-carboxylic acid amide 175 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 385.1 [(5-methyl-furan-2-yl)-methyl]-pyridine-3- carboxylic acid amide 176 N-[(4-Fluorophenyl)-methyl]-2-[[3-(4- 169 413.1 fluorophenyl)-1-methyl-propyl]sulfanyl]- pyridine-3-carboxylic acid amide 177 2-[[3-(4-Fluorophenyl)-1-methyl- 169 375.2 propyl]sulfanyl]-N-(3-methyl-butyl)- pyridine-3-carboxylic acid amide 178 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2- 169 413.2 [[3-(4-fluorophenyl)-1-methyl- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 179 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 411.1 propyl]sulfanyl]-N-(tetrahydro-furan-2-yl- methyl)-pyridine-3-carboxylic acid amide 180 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 425.1 propyl]sulfanyl]-N-(tetrahydro-pyran-2-yl- methyl)-pyridine-3-carboxylic acid amide 181 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 375.1 (tetrahydro-furan-2-yl-methyl)-pyridine-3- carboxylic acid amide 182 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N- 169 405.2 (2-methoxy-3,3-dimethyl-butyl)-pyridine- 3-carboxylic acid amide 183 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 431.1 propyl]sulfanyl]-N-(m-tolyl-methyl)- pyridine-3-carboxylic acid amide 184 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 445.1 propyl]sulfanyl]-N-[(3,5-dimethyl-phenyl)- methyl]-pyridine-3-carboxylic acid amide 185 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 369.1 propyl]sulfanyl]-N-propyl-pyridine-3- carboxylic acid amide 186 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 411.2 propyl]sulfanyl]-N-hexyl-pyridine-3- carboxylic acid amide 187 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 411.1 propyl]sulfanyl]-N-(tetrahydro-furan-3-yl- methyl)-pyridine-3-carboxylic acid amide 188 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 425.1 propyl]sulfanyl]-N-(tetrahydro-pyran-3-yl- methyl)-pyridine-3-carboxylic acid amide 189 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 425.1 propyl]sulfanyl]-N-(tetrahydro-pyran-4-yl- methyl)-pyridine-3-carboxylic acid amide 190 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 407.1 propyl]sulfanyl]-N-(furan-2-yl-methyl)- pyridine-3-carboxylic acid amide 191 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 421.1 propyl]sulfanyl]-N-[(5-methyl-furan-2-yl)- methyl]-pyridine-3-carboxylic acid amide 192 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 397.1 propyl]sulfanyl]-N-pentyl-pyridine-3- carboxylic acid amide 193 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 413.1 propyl]sulfanyl]-N-(3-methoxy-butyl)- pyridine-3-carboxylic acid amide 194 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 399.1 propyl]sulfanyl]-N-(2-methoxy-propyl)- pyridine-3-carboxylic acid amide 195 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 413.1 propyl]sulfanyl]-N-(2-methoxy-butyl)- pyridine-3-carboxylic acid amide 196 3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 413.1 propyl]sulfanyl]-pyridine-3- carbonyl]amino]-propionic acid methyl ester 197 3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)- 131 399.1 propyl]sulfanyl]-pyridine-3- carbonyl]amino]-propionic acid 198 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 398.1 propyl]sulfanyl]-N-(2- dimethylaminoethyl)-pyridine-3- carboxylic acid amide 199 2-[[3-(3,4-Difluoro-phenyl)-1-methyl- 169 431.1 propyl]sulfanyl]-N-[(4-fluorophenyl)- methyl]-pyridine-3-carboxylic acid amide 200 2-[[3-(3,4-Difluoro-phenyl)-1-methyl- 169 393.2 propyl]sulfanyl]-N-(3-methyl-butyl)- pyridine-3-carboxylic acid amide 201 N-[(4-Fluorophenyl)-methyl]-2-[[3-(3- 169 413.1 fluorophenyl)-1-methyl-propyl]sulfanyl]- pyridine-3-carboxylic acid amide 202 2-[[3-(3-Fluorophenyl)-1-methyl- 169 375.2 propyl]sulfanyl]-N-(3-methyl-butyl)- pyridine-3-carboxylic acid amide 203 N-(3-Methyl-butyl)-2-[[1-methyl-3-[3- 169 425.2 (trifluoromethyl)phenyl]-propyl]sulfanyl]- pyridine-3-carboxylic acid amide 204 2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro- 169 453.1 propyl]sulfanyl]-N-[(4-fluorophenyl)- methyl]-pyridine-3-carboxylic acid amide 205 N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2- 169 435.2 [[3,3-difluoro-3-(4-fluorophenyl)- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 206 N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2-[3- 169 399.2 (4-fluorophenyl)-propylsulfanyl]-pyridine- 3-carboxylic acid amide 207 N-[(4-Fluorophenyl)-methyl]-2-[3-[3- 169 449.1 (trifluoromethyl)phenyl]-propylsulfanyl]- pyridine-3-carboxylic acid amide 208 N-(3-Methyl-butyl)-2-[3-[3- 169 411.2 (trifluoromethyl)phenyl]-propylsulfanyl]- pyridine-3-carboxylic acid amide 209 2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro- 169 415.1 propyl]sulfanyl]-N-(3-methyl-butyl)- pyridine-3-carboxylic acid amide 210 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2- 169 453.2 [[3-(3,4-difluoro-phenyl)-3,3-difluoro- propyl]sulfanyl]-pyridine-3-carboxylic acid amide 211 2-[[3,3-Difluoro-3-(4-fluorophenyl)- 169 371.1 propyl]sulfanyl]-N-(2-hydroxy-ethyl)- pyridine-3-carboxylic acid amide 224 N-[(4-Fluoro-2-methoxy-phenyl)-methyl]- 169 429.1 2-[3-(4-fluorophenyl)-propylsulfanyl]- pyridine-3-carboxylic acid amide

Pharmacological Experiments Fluorescence Assay Using a Voltage Sensitive Dye

Human CHO-K₁ cells expressing KCNQ2/3 channels are cultivated adherently at 37° C., 5% CO₂ and 95% humidity in cell culture bottles (e.g. 80 cm² TC flasks, Nunc) with DMEM-high glucose (Sigma Aldrich, D7777) including 10% FCS (PAN Biotech, e.g. 3302-P270521) or alternatively MEM Alpha Medium (1×, liquid, Invitrogen, #22571), 10% fetal calf serum (FCS) (Invitrogen, #10270-106, heat-inactivated) and the necessary selection antibiotics.

Before being sown out for the measurements, the cells are washed with a 1×DPBS buffer without Ca²⁺/Mg²⁺(e.g. Invitrogen, #14190-094) and detached from the bottom of the culture vessel by means of Accutase (PAA Laboratories, #L11-007) (incubation with Accutase for 15 min at 37° C.). The cell count then present is determined using a CASY™ cell counter (TCC model, Schärfe System) in order subsequently to apply, depending on the density optimization for the individual cell line, 20,000-30,000 cells/well/100 ml of the described nutrient medium to 96-well measuring plates of the Corning™ CellBIND™ type (Flat Clear Bottom Black Polystyrene Microplates, #3340). Incubation is then carried out for one hour at room temperature, without gassing or adjusting the humidity, followed by incubation for 24 hours at 37° C., 5% CO₂ and 95% humidity.

The voltage-sensitive fluorescent dye from the Membrane Potential Assay Kit (Red™ Bulk format part R8123 for FLIPR, MDS Analytical Technologies™) is prepared by dissolving the contents of a vessel Membrane Potential Assay Kit Red Component A in 200 ml of extracellular buffer (ES buffer, 120 mM NaCl, 1 mM KCl, 10 mM HEPES, 2 mM CaCl₂, 2 mM MgCl₂, 10 mM glucose; pH 7.4). After removal of the nutrient medium, the cells are washed with 200 μl of ES buffer, then covered with a layer of 100 ml of the dye solution prepared above and incubated for 45 min at room temperature with the exclusion of light.

The fluorescence measurements are carried out with a BMG Labtech FLUOstar™ BMG Labtech NOVOstar™ or BMG Labtech POLARstar™ instrument (525 nm excitation, 560 nm emission, Bottom Read mode). After incubation of the dye, 50 ml of the test substances in the desired concentrations, or 50 μl of ES buffer for control purposes, are introduced into separate cavities of the measuring plate and incubated for 30 min at room temperature while being shielded from light. The fluorescence intensity of the dye is then measured for 5 min and the fluorescence value F₁ of each well is thus determined at a given, constant time. 15 μl of a 100 mM KCl solution (final concentration 92 mM) are then added to each well. The change in fluorescence is subsequently measured until all the relevant measured values have been obtained (mainly 5-30 min). At a given time after KCl application, a fluorescence value F₂ is determined, in this case at the time of the fluorescence peak.

For calculation, the fluorescence intensity F₂ is compared with the fluorescence intensity F₁, and the agonistic activity of the target compound on the potassium channel is determined therefrom. F₂ and F₁ are calculated as follows:

${\left( \frac{F_{2} - F_{1}}{F_{1}} \right) \times 100} = {\frac{\Delta \; F}{F}(\%)}$

In order to determine whether a substance has agonistic activity,

$\frac{\Delta \; F}{F},$

for example, can be compared with

$\left( \frac{\Delta \; F}{F} \right)_{K}$

of control cells.

$\left( \frac{\Delta \; F}{F} \right)_{K}$

is determined by adding to the reaction batch only the buffer solution instead of the test substance, determining the value F_(1K) of the fluorescence intensity, adding the potassium ions as described above, and measuring a value F_(2K) of the fluorescence intensity. F_(2K) and F_(1K) are then calculated as follows:

${\left( \frac{F_{2K} - F_{1K}}{F_{1K}} \right) \times 100} = {\left( \frac{\Delta \; F}{F} \right)_{K}(\%)}$

A substance has an agonistic activity on the potassium channel when

$\frac{\Delta \; F}{F}$

is greater than

$\left( \frac{\Delta \; F}{F} \right)_{K}:$

${\frac{\Delta \; F}{F}\;\rangle}\left( \frac{\Delta \; F}{F} \right)_{K}$

Independently of the comparison of

$\frac{\Delta \; F}{F}\mspace{14mu} {with}\mspace{14mu} \left( \frac{\Delta \; F}{F} \right)_{K}$

it is possible to conclude that a target compound has agonistic activity if an increase in

$\frac{\Delta \; F}{F}$

is to be observed as the dosage of the target compound increases.

Calculations of EC₅₀ values are carried out with the aid of ‘Prism v4.0’ software (GraphPad Software™).

Low-Intensity Tail Flick in the Rat

The antinociceptive effectiveness of the test substance towards an acute, noxious thermal stimulus was studied in the focal ray (tail flick) test in the rat according to the method of D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941)). Male Sprague-Dawley rats (breeder: Janvier, Le Genest St. Isle, France) weighing from 200 to 250 g were used for this purpose. The animals were accommodated individually in special test compartments and the base of the tail was exposed to the focused ray of an analgesia meter (model 2011, Rhema Labortechnik, Hofheim, Germany). 10 animals were used per group. Before a substance according to the invention was administered, the withdrawal latency (time from switching on of the focal ray to the sudden withdrawal of the tail) was determined twice at an interval of five minutes and the mean value was defined as the control latency time. The intensity of the focal ray was chosen so that the control latency time was 7 to 9 seconds. Measurement of the withdrawal latency was then repeated 10, 20, 30 and 60 minutes after peroral administration of substance. The antinociceptive action of the test substance was determined as the increase in the withdrawal latency time according to the following formula:

MPE[%]=[(T ₁ −T ₀)/(T ₂ −T ₀)]×100

where: T₀=control latency time before administration of substance, T₁=latency time after administration of substance, T₂=maximum exposure time to the focal ray (30 seconds), MPE=maximum possible effect.

Variance analysis (repeated measures ANOVA) was used to test for statistically significant differences between the substance group and the vehicle group. The level of significance was set at ≦0.05.

Pharmacological Data

The results from the pharmacological models described above are summarized in Table 3.

TABLE 3 Low- intensity Fluorimetry tail flick % efficacy rat p.o. Fluorimetry (retigabine % effect Exemplary EC₅₀ 50 μM = (dose compound [nM] 100%) [mg/kg]) 1 170 132 2 1349 97 3 53 4 772 126 5 435 161 7 91 8 37 9 1354 157 10 13 12 2919 170 13 302 200 16 74 176 17 128 176 18 111 160 19 37 171 20 49 174 21 364 126 22 2350 150 23 3766 163 24 11 122 25 1016 216 26 126 244 27 85 210 18 (10.0) 28 1571 192 29 275 159 30 630 261 31 437 98 32 3125 191 33 451 242 34 463 204 35 242 221 36 45 78 37 74 89 38 144 176 39 250 250 40 129 144 26 (21.5) 41 157 159 42 128 164 43 896 46 44 2962 167 45 1606 224 46 672 238 47 218 183 48 148 183 49 231 174 50 1491 169 51 198 192 49 (21.5) 52 496 190 53 302 220  0 (10.0) 54 133 240 20 (10.0) 55 227 149 56 1014 251 57 252 83 58 3875 174 59 210 83 60 263 236 61 221 283 62 182 274 63 34 72 64 49 100 65 40 97 49 (10.0) 66 50 121 67 113 290 68 65 280 32 (10.0) 69 140 259 70 244 308 71 72 107 72 85 85 73 377 268 74 62 260 75 37 261 76 33 77 233 118 78 319 53 79 101 103 80 77 104 81 8023 89 82 6457 96 83 139 171 84 3512 55 85 394 59 86 26 87 101 116 88 3759 53 89 5447 72 90 37 91 184 241 92 138 270 93 2809 154 94 2215 181 95 2061 147 96 660 194 97 134 196 98 29 99 178 70 100 1592 48 101 38 102 456 111 103 111 129 104 361 87 105 479 166 106 191 95 107 57 119 20 (21.5) 108 165 143 109 180 129 110 462 110 111 11061 61 112 494 104 113 5199 90 114 553 128 115 42 213 116 62 186 ED₅₀ 5.4 117 35 160 118 37 159 119 30 120 307 61 121 256 99 122 153 94 123 155 168 124 17 114 ED₅₀ 3.5 125 1404 99 126 627 177 127 1857 147 128 1846 122 129 325 122 130 465 164 131 25 132 82 120 133 106 185 61 (10.0) 134 268 224 40 (21.5) 135 3143 154 136 28 137 366 93 138 417 92 139 101 81 140 312 88 141 12773 86 142 97 260 143 1513 175 144 815 215 145 1493 174 146 2551 193 147 34 148 1958 85 149 93 181 150 1492 96 151 667 95 152 1292 89 153 1251 155 154 237 207 155 657 159 156 110 249 157 88 158 30 159 670 113 160 228 74 161 145 67 162 166 83 163 537 89 164 32 287 20 (4.64) 165 30 119 166 46 206 167 2714 77 168 17 110 169 19 224 ED₅₀ 2.7 170 24 229 20 (4.64) 171 432 181 172 1046 196 173 156 185 174 134 213 175 126 173 176 40 108 177 76 192 178 96 270 179 378 234 180 47 224 64 (10.0) 181 1552 254 182 366 110 183 43 109 184 23 185 167 212 186 236 191 187 805 231 188 315 210 189 287 161 190 26 214 191 37 202 192 32 195 193 371 206 194 232 203 195 48 122 196 3710 190 197 14717 128 198 8840 110 199 20 124 200 40 230 201 40 128 202 71 235 203 20 233 204 11 125 205 28 294 206 40 293 207 34 119 208 27 207 209 9 228 210 14 276 211 8828 87 212 427 184 

1. A substituted nicotinamide of the formula (1):

wherein A¹ represents CR¹⁰R¹¹ or S; A² represents CR¹²R¹³, C(═O), O, S, S(═O) or S(═O)₂; represents C₁₋₁₀-alkyl or C₂₋₁₀-heteroalkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; or C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted, wherein the alkyl or heteroalkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or poly-substituted; R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; CH₂—O-methyl; CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl, or S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; NR^(a)R^(b), wherein R^(a) and R^(b) each independently of the other represents H or C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted, or R^(a) and R^(b), together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; C₁₋₁₀-alkyl, C₂₋₁₀-heteroalkyl, O—C₁₋₁₀-alkyl or S—C₁₋₁₀-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; C₃₋₁₀-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; with the proviso that when R⁵, R⁶, R⁷ and R⁸ each denotes H and A¹ represents S, A² may not denote S, S(═O) or S(═O)₂; or R⁵ and R⁶ or R⁷ and R⁸ or R¹⁰ and R¹¹ or R¹² and R¹³ or R⁵ and R¹¹ or R⁵ and R⁷ or R⁵ and R¹³ or R⁷ and R¹³ or R⁷ and R¹¹ or R¹¹ and R¹³, together with the carbon atom(s) joining them, form a C₃₋₈-cycloalkyl or a heterocyclyl having from three to eight ring members, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; wherein the remaining substituents R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ in each case have the meaning given above; R⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted; or represents CR^(c)R^(d), wherein R^(c) and R^(d) each independently of the other denotes C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted; with the proviso that when A² represents O or S and R⁹ represents heterocyclyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted; or heteroaryl, unsubstituted or mono- or poly-substituted, the heteroaryl or heterocyclyl is bound via a carbon atom of the heteroaryl or heterocyclyl; wherein “substituted” in the case of substitution on alkyl, heteroalkyl, heterocyclyl and cycloalkyl stands for the substitution of one or more hydrogen atoms, in each case independently of one another, by F; Cl; Br; I; NO₂; CF₃; CN; ═O; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; and S(═O)₂—NH—C₁₋₈-heteroaryl; wherein “substituted” in the case of substitution on aryl or heteroaryl stands for the substitution of one or more hydrogen atoms, in each case independently of one another, by F; Cl; Br; I; NO₂; CF₃; CN; C₁₋₈-alkyl; C₂₋₈-heteroalkyl; aryl; heteroaryl; C₃₋₁₀-cycloalkyl; heterocyclyl; C₁₋₈-alkyl- or C₂₋₈-heteroalkyl-bridged aryl, heteroaryl, C₃₋₁₀-cycloalkyl or heterocyclyl; CHO; C(═O)C₁₋₈-alkyl; C(═O)aryl; C(═O)heteroaryl; CO₂H; C(═O)O—C₁₋₈-alkyl; C(═O)O-aryl; C(═O)O-heteroaryl; CONH₂; C(═O)NH—C₁₋₈-alkyl; C(═O)N(C₁₋₈-alkyl)₂; C(═O)NH-aryl; C(═O)N(aryl)₂; C(═O)NH-heteroaryl; C(═O)N(heteroaryl)₂; C(═O)N(C₁₋₈-alkyl)(aryl); C(═O)N(C₁₋₈-alkyl)(heteroaryl); C(═O)N(heteroaryl)(aryl); OH; O—C₁₋₈-alkyl; OCF₃; O—(C₁₋₈-alkyl)-OH; O—(C₁₋₈-alkyl)-O—C₁₋₈-alkyl; O-benzyl; O-aryl; O-heteroaryl; O—C(═O)C₁₋₈-alkyl; O—C(═O)aryl; O—C(═O)heteroaryl; NH₂; NH—C₁₋₈-alkyl; N(C₁₋₈-alkyl)₂; NH—C(═O)C₁₋₈-alkyl; N(C₁₋₈-alkyl)-C(═O)C₁₋₈-alkyl; N(C(═O)C₁₋₈-alkyl)₂; NH—C(═O)-aryl; NH—C(═O)-heteroaryl; SH; S—C₁₋₈-alkyl; SCF₃; S-benzyl; S-aryl; S-heteroaryl; S(═O)₂C₁₋₈-alkyl; S(═O)₂aryl; S(═O)₂heteroaryl; S(═O)₂OH; S(═O)₂O—C₁₋₈-alkyl; S(═O)₂O-aryl; S(═O)₂O-heteroaryl; S(═O)₂—NH—C₁₋₈-alkyl; S(═O)₂—NH-aryl; or S(═O)₂—NH—C₁₋₈-heteroaryl; said substituted nicotinamide being in the form of a free compound or a salt of physiologically acceptable acids or bases.
 2. The substituted nicotinamide according to claim 1, wherein A¹ represents S; and A² represents CR¹²R¹³, O, S or S(═O)₂.
 3. The substituted nicotinamide according to claim 1, wherein R¹ represents the partial structure (T1)

wherein R^(14a) and K^(14b) each independently of the other represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; NH₂; C₁₋₄-alkyl, O—C₁₋₄-alkyl, NH—C₁₋₄-alkyl, or N(C₁₋₄-alkyl)₂, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, O—C₁₋₄-alkyl, OH and OCF₃; C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH, ═O, O—-C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and N(C₁₋₄-alkyl)₂; m represents 0, 1, 2 or 3; Y represents O or NR¹⁵, wherein R¹⁵ represents H; C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and N(C₁₋₄-alkyl)₂; or represents C₃₋₁₀-cycloalkyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, C₁₋₄-alkyl, OH, O—C₁₋₄-alkyl, OCF₃, NH₂, NH—C₁₋₄-alkyl and N(C₁₋₄-alkyl)₂; n represents 0 or 1, B represents C₁₋₈-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, ═O, O—-C₁₋₄-alkyl, OCF₃, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH; C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, S—C₁₋₈-alkyl, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, SCF₃ and S(═O)₂OH; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, SCF₃, S(═O)₂OH, benzyl, phenyl, pyridyl and thienyl, wherein benzyl, phenyl, pyridyl, thienyl can in each case be unsubstituted or mono- or poly-substituted by one or more substituents selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₈-alkyl, OCF₃, C₁₋₈-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₈-alkyl), N(C₁₋₈-alkyl)₂, SH, SCF₃ and S(═O)₂OH.
 4. The substituted nicotinamide according to claim 3, wherein R^(14a) and R^(14b) each independently of the other represents H; F; Cl; Br; I; NO₂; CF₃; CN; methyl; ethyl; n-propyl; isopropyl; cyclopropyl; n-butyl; sec-butyl; tert-butyl; CH₂CF₃; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; OCF₃; NH₂; NH-methyl; N(methyl)₂; NH-ethyl; N(ethyl)₂; or N(methyl)(ethyl); m represents 0, 1 or 2; n represents 0; and B represents C₁₋₄-alkyl, saturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, OCF₃ and CF₃; C₃₋₁₀-cycloalkyl, saturated, unsubstituted; phenyl, naphthyl, pyridyl, thienyl, in each case unsubstituted or mono- or di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃, and S(═O)₂OH.
 5. The substituted nicotinamide according to claim 1, wherein R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; CH₂—O-methyl; CH₂—OH; C₂₋₆-alkyl, O—C₁₋₆-alkyl, or S—C₁₋₆-alkyl, in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, ═O and O—C₁₋₄-alkyl; C₃₋₇-cycloalkyl, saturated or unsaturated, branched or unbranched, unsubstituted; NR^(a)R^(b), wherein R^(a) and R^(b) each independently of the other represents H or C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of OH, ═O and O—C₁₋₄-alkyl, or R^(a) and R^(b), together with the nitrogen atom joining them, form a heterocyclyl, saturated or unsaturated, unsubstituted or mono- or poly-substituted by C₁₋₄-alkyl.
 6. The substituted nicotinamide according to claim 5, wherein R², R³ and R⁴ each independently of the others represents H; F; Cl; Br; I; methyl; ethyl; n-propyl, isopropyl; cyclopropyl; CN; CF₃; O-methyl; OCF₃; S-methyl; or SCF₃.
 7. The substituted nicotinamide according to claim 1, wherein R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; Br; I; NO₂; CF₃; CN; OH; OCF₃; SH; SCF₃; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; O—(CH₂)₂—OH; S-methyl; S-ethyl; cyclopropyl; cyclobutyl; cyclopentyl; or cyclohexyl; or R⁵ and R⁶ or R⁷ and R⁸ or R¹⁰ and R¹¹ or R¹² and R¹³ or R⁵ and R¹¹ or R⁵ and R⁷ or R⁵ and R¹³ or R⁷ and R¹³ or R⁷ and R¹¹ or R¹¹ and R¹³, together with the carbon atom(s) joining them, form a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in each case unsubstituted; wherein the remaining substituents R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ in each case have the meaning given above.
 8. The substituted nicotinamide according to claim 1, wherein R⁹ represents C₃₋₁₀-cycloalkyl or heterocyclyl, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, ═O, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃; aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl and SCF₃; or represents CR^(c)R^(d), wherein R^(c) and R^(d) each independently of the other denotes C₁₋₄-alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-alkyl, CF₃, OCF₃ and SCF₃.
 9. The substituted nicotinamide according to claim 1, wherein R⁹ represents phenyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.
 10. The substituted nicotinamide according to claim 1, wherein A¹ represents S and A² represents CR¹²R¹³; R¹ represents the partial structure (T1-1)

wherein R^(14a) and R^(14b) each independently of the other represents H; F; Cl; Br; I; methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; OH; O-methyl; O-ethyl; O—(CH₂)₂—O—CH₃; or O—(CH₂)₂—OH; m represents 0, 1 or 2; B represents methyl; ethyl; n-propyl; isopropyl; n-butyl; sec-butyl; tert-butyl; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicyclo[2.2.2]octyl; phenyl, pyridyl, thienyl, in each case unsubstituted or mono-, di- or tri-substituted by one, two or three substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO₂, CN, OH, O—C₁₋₄-alkyl, OCF₃, C₁₋₄-alkyl, C(═O)—OH, CF₃, NH₂, NH(C₁₋₄-alkyl), N(C₁₋₄-alkyl)₂, SH, S—C₁₋₄-alkyl, SCF₃ and S(═O)₂OH; R², R³ and R⁴ each independently of the others represents H; F; Cl; methyl; ethyl; CF₃ or O-methyl; R⁵, R⁶, R⁷, R⁸, R¹⁰, R¹¹, R¹² and R¹³ each independently of the others represents H; F; Cl; methyl; ethyl; n-propyl, isopropyl; or cyclopropyl; R⁹ represents phenyl, pyridyl or thienyl, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, CN, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, O-methyl, O-ethyl, O-n-propyl, O-isopropyl, O-butyl, O-sec-butyl, O-tert-butyl, OH, OCF₃, CF₃, SH, S—C₁₋₄-alkyl and SCF₃.
 11. The substituted nicotinamide according to claim 1, selected from the group consisting of: 1 2-(3-Phenyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 2 2-(3-Cyclohexyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 3 2-[(3-Oxo-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 4 N-(Thiophen-2-yl-methyl)-2-[2-[3-(trifluoromethyl)-phenoxy]-ethylsulfanyl]-pyridine-3-carboxylic acid amide; 5 2-(4-Methyl-pentylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 7 2-(4-Phenyl-butyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 8 2-[3-(Benzenesulfonyl)-propyl]-N-(cyclohexyl-methyl)-pyridine-3-carboxylic acid amide; 9 N-(Cyclohexyl-methyl)-2-(4-phenyl-butyl)-pyridine-3-carboxylic acid amide; 10 2-[3-(Benzenesulfonyl)-propyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 12 N-(Thiophen-2-yl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic acid amide; 13 N-(Thiophen-2-yl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfanyl]-propyl]-pyridine-3-carboxylic acid amide; 16 2-(2-Phenylsulfanyl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 17 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 18 N-(Thiophen-2-yl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide; 19 2-[2-[(4-Fluorophenyl)sulfanyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 20 N-(Thiophen-2-yl-methyl)-2-[2-[[3-(trifluoromethyl)phenyl]sulfanyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide; 21 N-(Thiophen-2-yl-methyl)-2-[4-[3-(trifluoromethyl)-phenyl]-butyl]-pyridine-3-carboxylic acid amide; 22 2-[4-(4-Fluorophenyl)-butyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 23 2-(3-Phenylsulfanyl-propyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 24 2-[(1-Methyl-2-phenylsulfanyl-ethyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide; 25 N-(Cycloheptyl-methyl)-2-[4-[3-(trifluoromethyl)phenyl]-butyl]-pyridine-3-carboxylic acid amide 26 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[4-[3-(trifluoromethyl)phenyl]-butyl]-pyridine-3-carboxylic acid amide 27 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 28 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(4-methyl-pentylsulfanyl)-pyridine-3-carboxylic acid amide 29 N-(Cycloheptyl-methyl)-2-[3-[(4-fluorophenyl)sulfanyl]-propyl]-pyridine-3-carboxylic acid amide 30 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[(4-fluorophenyl)sulfanyl]-propyl]pyridine-3-carboxylic acid amide 31 N-(Cycloheptyl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic acid amide 32 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[[3-(trifluoromethyl)phenyl]sulfonyl]-propyl]-pyridine-3-carboxylic acid amide 33 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3-phenyl-propylsulfanyl)-pyridine-3-carboxylic acid amide 34 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[4-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 35 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-chlorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 36 N-[(3,5-Difluoro-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 37 N-[(5-Chloro-thiophen-2-yl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 38 N-[(2,2-Dimethyl-cyclopropyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 39 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 40 N-(Cyclohexyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 41 N-(Cycloheptyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 43 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-3-oxo-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 44 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[(3-oxo-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic acid amide 45 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(hexylsulfanyl)-pyridine-3-carboxylic acid amide 46 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(2-phenoxy-ethylsulfanyl)-pyridine-3-carboxylic acid amide 47 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2-[3-(trifluoromethyl)-phenoxy]-ethylsulfanyl]-pyridine-3-carboxylic acid amide 48 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3,3,3-trifluoro-propyl)-pyridine-3-carboxylic acid amide 49 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[2-(4-fluoro-phenoxy)-ethylsulfanyl]-pyridine-3-carboxylic acid amide 52 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-(3-naphthalen-1-yl-propylsulfanyl)-pyridine-3-carboxylic acid amide 53 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-fluoro-4-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 54 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[4-fluoro-3-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 55 N-(Cyclooctyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 56 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-methoxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 57 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-methoxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 59 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(trifluoromethyl)phenyl]-methyl]-pyridine-3-carboxylic acid amide 60 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,4-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 61 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,5-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 62 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(2,4-difluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 63 N-[(2-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 64 N-[(3-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 65 N-[(4-Fluorophenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 66 N-Benzyl-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 67 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[(1-methyl-3-phenyl-propyl)sulfanyl]-pyridine-3-carboxylic acid amide 68 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3,4,5-trifluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 69 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-fluoro-5-(trifluoromethyl)-phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 70 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-methoxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 71 N-[(3,4-Difluoro-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 72 N-(2,3-Dihydro-benzofuran-5-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 73 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(3-hydroxyphenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 74 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 75 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-2-methyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 76 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(2-methoxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 77 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-methoxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 78 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-phenethyl-pyridine-3-carboxylic acid amide 79 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[4-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic acid amide 80 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[4-(trifluoromethyl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide 81 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-3-yl-ethyl)-pyridine-3-carboxylic acid amide 82 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-2-yl-ethyl)-pyridine-3-carboxylic acid amide 83 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(2-hydroxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 84 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-hydroxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 85 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(m-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 86 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(o-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 87 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(trifluoromethyloxy)-phenyl]-methyl]-pyridine-3-carboxylic acid amide 88 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-hydroxyphenyl)-methyl]-pyridine-3-carboxylic acid amide 89 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-pyridine-4-yl-ethyl)-pyridine-3-carboxylic acid amide 90 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[2-(p-tolyl)-ethyl]-pyridine-3-carboxylic acid amide 91 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-butylsulfanyl]-pyridine-3-carboxylic acid amide 92 N-(5-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(2,4,5-trifluoro-phenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 93 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-2-yl-propyl)-pyridine-3-carboxylic acid amide 94 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-3-yl-propyl)-pyridine-3-carboxylic acid amide 95 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-pyridine-4-yl-propyl)-pyridine-3-carboxylic acid amide 96 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-propyl-pyridine-3-carboxylic acid amide 97 N-Butyl-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 98 2-(3-Pyridin-3-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 99 2-[3-(p-Tolyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 100 2-(4-Phenyl-butylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 101 2-(3-Pyridin-4-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 102 2-(3-Naphthalen-2-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 103 2-[3-(m-Tolyl)-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 104 N-(Thiophen-2-yl-methyl)-2-(3-thiophen-2-yl-propylsulfanyl)-pyridine-3-carboxylic acid amide 105 2-[(1-Methyl-3-phenyl-propyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 106 N-(Thiophen-2-yl-methyl)-2-(3-thiophen-3-yl-propylsulfanyl)-pyridine-3-carboxylic acid amide 107 2-[[1-Methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 108 2-[(2-Benzyl-cyclohexyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 109 2-[3-[3-Methyl-5-(trifluoromethyl)-phenyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 110 2-[4-(3,4-Difluoro-phenyl)-butylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 111 2-(3-Pyridin-2-yl-propylsulfanyl)-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 113 2-[3-[4-Methyl-3-(trifluoromethyl)-phenyl]-propylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 114 2-[(3-Phenyl-cyclohexyl)sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 116 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide 117 N-(Cycloheptyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 118 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-3-carboxylic acid amide 119 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(1,2,3,4-tetrahydro-naphthalen-2-yl-methyl)-pyridine-3-carboxylic acid amide 120 N-(2,3-Dihydro-1H-inden-2-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 121 N-(1,3-Benzodioxol-5-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 122 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-phenyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 123 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-methyl-cyclohexyl)-methyl]-pyridine-3-carboxylic acid amide 124 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic acid amide 125 N-(3,3-Dimethyl-2-oxo-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 127 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(pyridin-3-yl-methyl)-pyridine-3-carboxylic acid amide 128 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(pyridin-4-yl-methyl)-pyridine-3-carboxylic acid amide 129 3-[[[2-[3-(4-Fluorophenyl)-propylsulfanyl]-pyridine-3-carbonyl]amino]-methyl]-benzoic acid methyl ester 130 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(2-methoxyphenyl)-propyl]-pyridine-3-carboxylic acid amide 132 N-[(4-Fluorophenyl)-methyl]-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 133 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide 134 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(tetrahydro-pyran-2-yl-methyl)-pyridine-3-carboxylic acid amide 135 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-pyrazol-1-yl)-propyl]-pyridine-3-carboxylic acid amide 136 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(naphthalen-2-yl-methyl)-pyridine-3-carboxylic acid amide 137 N-(2,3-Dihydro-[1,4]benzodioxin-6-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 138 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-morpholin-4-yl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 139 N-(2,3-Dihydro-benzofuran-6-yl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 140 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[[3-(1H-pyrazol-1-yl)-phenyl]-methyl]-pyridine-3-carboxylic acid amide 141 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-[1,2,3]triazol-1-yl)-propyl]-pyridine-3-carboxylic acid amide 142 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 144 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiazol-2-yl-methyl)-pyridine-3-carboxylic acid amide 145 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(thiazol-5-yl-methyl)-pyridine-3-carboxylic acid amide 146 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(oxazol-2-yl-methyl)-pyridine-3-carboxylic acid amide 148 N-(3,3-Dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-4-methyl-pyridine-3-carboxylic acid amide 149 N-(3,3-Dimethyl-butyl)-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 150 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(quinolin-7-yl-methyl)-pyridine-3-carboxylic acid amide 151 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-2-yl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 152 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-3-yl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 153 N-(3,3-Dimethyl-butyl)-2-[[(1R)-1-methyl-3-phenyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 154 N-(3,3-Dimethyl-butyl)-2-[[(1S)-1-methyl-3-phenyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 155 2-[(2-Benzyl-cyclopentyl)sulfanyl]-N-(3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide 156 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 157 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[3-(1H-[1,2,4]triazol-1-yl)-propyl]-pyridine-3-carboxylic acid amide 158 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-([1,3,4]oxadiazol-2-yl-methyl)-pyridine-3-carboxylic acid amide 159 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(3-pyridin-4-yl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 160 N-[[4-(Cyclopropyl-methyl)-3,4-dihydro-2H-[1,4]benzoxazin-6-yl]-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 161 N-[(4-Ethyl-3,4-dihydro-2H-[1,4]benzoxazin-6-yl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 162 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(4-methyl-3,4-dihydro-2H-[1,4]benzoxazin-6-yl)-methyl]-pyridine-3-carboxylic acid amide 163 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(3-methyl-3-phenyl-butyl)-pyridine-3-carboxylic acid amide 164 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 165 2-[[3,3-Difluoro-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic acid amide 166 2-[[3,3-Difluoro-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-N-(3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide 168 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(3-fluorophenyl)-methyl]-pyridine-3-carboxylic acid amide 170 N-Butyl-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 171 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-ethyl)-pyridine-3-carboxylic acid amide 172 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-methoxy-ethyl)-pyridine-3-carboxylic acid amide 173 N-[(4-Fluoro-2-hydroxy-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 174 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(furan-2-yl-methyl)-pyridine-3-carboxylic acid amide 175 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-[(5-methyl-furan-2-yl)-methyl]-pyridine-3-carboxylic acid amide 176 N-[(4-Fluorophenyl)-methyl]-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 177 2-[[3-(4-Fluorophenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide 178 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(4-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 179 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-furan-2-yl-methyl)-pyridine-3-carboxylic acid amide 180 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-2-yl-methyl)-pyridine-3-carboxylic acid amide 181 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(tetrahydro-furan-2-yl-methyl)-pyridine-3-carboxylic acid amide 182 2-[3-(4-Fluorophenyl)-propylsulfanyl]-N-(2-methoxy-3,3-dimethyl-butyl)-pyridine-3-carboxylic acid amide 183 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(m-tolyl-methyl)-pyridine-3-carboxylic acid amide 184 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(3,5-dimethyl-phenyl)-methyl]-pyridine-3-carboxylic acid amide 185 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-propyl-pyridine-3-carboxylic acid amide 186 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-hexyl-pyridine-3-carboxylic acid amide 187 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-furan-3-yl-methyl)-pyridine-3-carboxylic acid amide 188 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-3-yl-methyl)-pyridine-3-carboxylic acid amide 189 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(tetrahydro-pyran-4-yl-methyl)-pyridine-3-carboxylic acid amide 190 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(furan-2-yl-methyl)-pyridine-3-carboxylic acid amide 191 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-[(5-methyl-furan-2-yl)-methyl]-pyridine-3-carboxylic acid amide 192 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-pentyl-pyridine-3-carboxylic acid amide 193 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methoxy-butyl)-pyridine-3-carboxylic acid amide 194 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-propyl)-pyridine-3-carboxylic acid amide 195 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-methoxy-butyl)-pyridine-3-carboxylic acid amide 196 3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carbonyl]amino]-propionic acid methyl ester 197 3-[[2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carbonyl]amino]-propionic acid 198 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-dimethylaminoethyl)-pyridine-3-carboxylic acid amide 199 2-[[3-(3,4-Difluoro-phenyl)-1-methyl-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic acid amide 200 2-[[3-(3,4-Difluoro-phenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide 201 N-[(4-Fluorophenyl)-methyl]-2-[[3-(3-fluorophenyl)-1-methyl-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 202 2-[[3-(3-Fluorophenyl)-1-methyl-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide 203 N-(3-Methyl-butyl)-2-[[1-methyl-3-[3-(trifluoromethyl)phenyl]-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 204 2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-N-[(4-fluorophenyl)-methyl]-pyridine-3-carboxylic acid amide 205 N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3,3-difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 206 N-(1-Bicyclo[2.2.1]heptanyl-methyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide 207 N-[(4-Fluorophenyl)-methyl]-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 208 N-(3-Methyl-butyl)-2-[3-[3-(trifluoromethyl)phenyl]-propylsulfanyl]-pyridine-3-carboxylic acid amide 209 2-[[3-(3,4-Difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-3-carboxylic acid amide 210 N-(7-Bicyclo[2.2.1]heptanyl-methyl)-2-[[3-(3,4-difluoro-phenyl)-3,3-difluoro-propyl]sulfanyl]-pyridine-3-carboxylic acid amide 211 2-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(2-hydroxy-ethyl)-pyridine-3-carboxylic acid amide 224 N-[(4-Fluoro-2-methoxy-phenyl)-methyl]-2-[3-(4-fluorophenyl)-propylsulfanyl]-pyridine-3-carboxylic acid amide and physiologically acceptable salts thereof.
 12. A pharmaceutical composition comprising at least one substituted nicotinamide according to claim 1, in each case in the form of an individual stereoisomer or a mixture thereof, in the form of a free compound and/or a physiologically acceptable salt thereof, and optionally one or more suitable additives and/or auxiliary substances and/or optionally further active ingredients.
 13. A method of treating a disorder in a patient in need of such treatment, said disorder being at least one disorder selected from the group consisting of pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, and dystonia-associated dyskinesias, said method comprising administering to said patient an amount effective to treat said disorder of at least one substituted nicotinamide according to claim 1, in each case in the form of an individual stereoisomer or a mixture thereof, and in the form of a free compound and/or a physiologically acceptable salt thereof.
 14. (canceled) 